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ABSTRACT

Pharmaceutical research includes investigation and development of a new drug and
determination of the delivery route and delivery system, as well as the technology to create the
delivery system. It can also consist of a combination of these steps. Researchers studying potential
delivery routes have explored oral, nasal, dermal, transdermal, transmucosal, pulmonary, and
injection routes for their ability to deliver large and small drug molecules. This research project
focuses on the oral route, which is generally accepted as an effective delivery route for many drug
products with a large market share, and studies the use of this route for the delivery of poorly
soluble actives. Conventional delivery systems used for oral drug delivery are solid dosage forms
including capsules filled with milled material, tablets, and pellets. Current research focusing on
actives with low aqueous solubility requires new technology to obtain tailored drug release. This
research project studies the use of hot melt extrusion (HME), together with hydrophilic polymers,
to improve availability of poorly soluble compounds.
In recent years HME has become widely accepted as a viable drug delivery system. HME
is useful for several different purposes, including solid-state stability enhancement, taste masking,
and solubility enhancement, and can be used in the production of a variety of drug dosage forms.
The use of HME for solubility enhancement is the subject of this research. Solubility enhancement
can be achieved by using HME to disperse a poorly soluble drug in a polymeric carrier matrix,
forming a solid dispersion. This method can be used to form both amorphous and crystalline
dispersions, but for solubility enhancement amorphous dispersions are
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used because of the free energy benefits associated with them. To create an amorphous solid
dispersion, a drug polymer is melt-extruded then cooled at a rate that prevents recrystallization or
processed at a temperature at which the melted drug is immiscible with the carrier. These processes
result in kinetic entrapment of the compound in its amorphous state, produce the highest level of
specific surface area, and increase saturation solubility, all of which work to improve drug
solubility. These processes provide the benefit of increased dissolution rate because of higher
thermodynamic activity, but the compounds still have the tendency to return to their crystalline
forms. In order to realize the full potential of HME processes in improving drug delivery, it is
necessary to have a comprehensive understanding of the physicochemical properties of the
amorphous solid dispersions and their In vitro behavior.
The most important application of HME technology in the pharmaceutical industry is for
developing multi-particulate drug delivery systems. These are primarily oral dosage forms which
consist of many, tiny, discrete units, each of which shows the desired characteristics. With multiparticulate systems the drug dosage is divided into multiple sub-units consisting of minute
spherical particles with a diameter of 0.05-2.00 millimeters, or mini-tablets with diameters from
2.00-5.00 mm.
The research project covered by this dissertation focuses on characterizing several
hydrophilic polymeric extrudates produced through HME, and highlighting their various
pharmaceutical applications. HME, when used together with an effective pelletizer, has been
shown to be a practicable method for the development of novel mini-tablet and pellet dosage forms.
Research concerning the use of HME for solubility enhancement focuses on producing amorphous
iii

solid dispersions using novel hydrophilic polymers and detailed description of the resulting meltextrudates. It also studies the effects of different formulation variables and process parameters on
the compounds produced. These lines of research aid in the development of modulated-drugrelease, stable solid oral dosage form.
The key objectives of the chapters in the dissertation are: (1) To Introduce Hot Melt
Extrusion as prominent technique in pharmaceutical industry; (2) To prepare novel taste-masked
mini-tablets of ketoprofen (KPR) with the taste-masking carrier Eudragit® E PO by HME and to
evaluate the effectiveness of the taste masking with multiple in vitro methods. In addition, FTIR
imaging was utilized to visually approximate drug homogeneity; (3) To formulate face-cut, melt
extruded pellets and to optimize hot melt process parameters on pellets to obtain maximized
sphericity and hardness utilizing Soluplus® as a polymeric carrier and carbamazepine (CBZ) as a
model drug; (4) To assess the potential of Lutrol® F grades as polymeric surfactants for solubility
enhancement of Kollidon®VA64 drug matrices produced by Hot Melt Extrusion.
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CHAPTER 1
INTRODUCTION
Hot melt Extrusion has been used in the manufacturing process for plastics and food since
the 1930s (Repka et al. 2007b). HME has been shown by a number of studies to be useful in the
production of pharmaceutical products using pellets, granules, mini-tablets, transmucosal, and
transdermal delivery systems and implants. Furthermore, HME is a continuous manufacturing
process that does not require drying or discontinuous steps in processing, making it extremely
efficient.
There are two types of extrusion, wet and dry, that can be used for extrusion processing.
With wet extrusion, the ingredients are mixed with a solvent such as water or alcohol which
activates a binder and forms a wet mass, which is extruded through a sieve. Pellets are created by
cutting and spheronizing the strands which result from extrusion through a sieve. The ripening
action of the excipients during wet extrusion produces a uniform product with a better finish than
dry-extruded products (Fielden, Newton, and Rowe 1992). Wet extrusion is also preferable for
use with heat-sensitive drugs and excipients because it reduces localized heat build-up. In contrast
to wet extrusion, dry extrusion does not use solvents, but rather utilizes a thermoplastic agent
which forms a homogenous matrix with the compounds when processed with a hot melt extruder.
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The most commonly used types of hot melt extruder in the pharmaceutical industry are
screw-base extruders, which use a screw running the length of the barrel to feed the extruded
material from the intake to the discharge plate, which also serves to efficiently mix the product.
The screw action not only facilitates feeding and conveying of the mixture through the
extruder, but also aids in blending the material and helps ensure uniform melting of the components
to produce a more homogenous extrudate.
There are two main types of screw extruders. The first are known as single screw extruders
because they use a single screw which rotates to mix and convey the material inside a heated barrel.
Single screw extruders can maintain consistent pressure even during the massive build-up of
pressure which occurs with highly viscous materials. Because they do tend to lose discharge
capacity where the screw tapers on the discharge end, especially with screw diameters smaller than
18 mm, single screw extruders usually have a motor on this end to improve discharge capacity
(Crowley, Zhang, Repka, Thumma, Upadhye, Kumar Battu, et al. 2007). All screw extruders are
made up of a barrel with the screw components inside, and a drive motor which runs the device.
The other common type of extruder is a twin screw extruder (TSE), which utilizes two
screws inside the barrel. These screws can be co-rotating (running in the same direction) or
counter-rotating (running in opposite directions). Twin screw extruders are favored in the
pharmaceutical industry because of their numerous advantages, including better feeding and
mixing, improved dispersion of materials, shorter residence time, lower heat generation, and
devolatilization. The choice between a co-rotating or counter-rotating extruder is made based on
the particular application. The advantages of co-rotating TSEs are their capacity for high speed
and reduced wear-and-tear on both the screws and the motors, as well as reduced localized heat
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generation in co-rotating TSE with intermeshing screws, which are self-cleaning. Counter-rotating
TSEs, on the other hand, cannot be operated at high speeds, experience extreme localized heat
generation which can result in degradation of the product, suffer from wear and tear cause by
outward push of the product inside the barrel, and can cause excessive air entrapment in the
extruded product. The benefits of counter-rotating TSE are high shear, intense mixing, and more
uniformly distributed components in the resulting extrudate.
The last important part of any the extrusion system is the die, a shaped or perforated
opening in a steel block at the discharge end of the extruder, which shapes the extruded material.
The die can serve additional functions as well by holding thermocouples, transducers, and probes
to help analyze the extrusion process (Saerens et al. 2011; Tumuluri et al. 2004). The die can have
different shapes, depending on the desired shape of the extruded material and the final dosage
form, and the temperature of the die has effects on the pressure and post-extrusion characteristics
of the extrudate. For this reason, controlling the die temperature is extremely important to achieve
the desired result; for example, with viscoelastic polymers, increasing the die temperature lowers
their viscosity and eases extrusion, because these polymers swell upon exiting the die.
In recent decades, a large number of new chemical entities (NCEs) have been discovered,
because of advances in computational chemistry and the development of high throughput
screening. According to the biopharmaceutical classification system (BCS) about 40% of NCEs
are Class II drugs with high permeability and low solubility. One of the most important and
challenge aspects of developing NCEs is the necessity of sufficient aqueous solubility. For this
reason, much effort has been put into improving the solubility of poorly water soluble compounds.
Various techniques that have been proposed and studied for this purpose include prodrugs (Sohma
et al. 2003), nanotechnology (Potta et al. 2010), complexation (Rawat and Jain 2004; Hamada et
3

al. 2006; Shikhar et al. 2011), co-crystal (Shikhar et al. 2011), solubilization using surfactants or
salts (Chang et al. 2004; Stephenson, Aburub, and Woods 2011) and solid dispersions (Patel et al.
2012; Miller et al. 2007; Maniruzzaman, Rana, et al. 2012; Sinha et al. 2010; Betageri and Makarla
1995). Because of its ability to improve the solubility and bio-availability of poorly water soluble
compounds, solid dispersion has acquired the attention of academia as well as the pharmaceutical
industry.
Solid dispersion is defined as dispersion of an API in an inert carrier or carriers or a
hydrophilic matrix, in a solid state. It has been successfully used as a delivery method for a wide
variety of poorly water soluble APIs to increase the exposure in experimental subjects (Serajuddin
1999). The research project covered by this dissertation studies the use of solid dispersion of a
variety of poorly water soluble drugs in several different hydrophilic polymeric carriers.
HME forms solid dispersions using thermoplastic polymers able to withstand shear and high
temperatures, sometimes with addition of processing aids that decrease the viscosity of the melted
matrix (Repka et al. 1999) form pores, or give the extruded matrix specific physico-mechanical
properties. HME is an efficient, continuous process which can be scaled-up without difficulty,
unlike other processes used in the pharmaceutical industry. The primary requirements for HME
are polymers and drugs which are thermostable, thermoplastic, and able to withstand the shear of
the extrusion screws.
When developing an HME process, the melt extrusion parameters have to be optimized
based on the specific goal, and the downstream processing must be optimized based on the desired
dosage form. Extrudates are often milled before being compressed into tablets, or filled into
capsules, though there are other final dosage forms available including die face pelletizing, shaping
calander, and strand cutting. The downstream processing is based on the target dosage form. This
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research project covers three different dosage forms all intended for oral administration. Chapter
2 studies a compound shaped into mini-tablets using a strand-cut pelletizer, while for chapter 3,
the strand was shaped into spherical pellets with a face cut pelletizer. Both these chapters include
further research on optimizing process parameters to guarantee process continuity. In chapter 4,
the extruded compound was milled into fine powder and filled into capsules.
Any delivery system is intended to provide a therapeutic dosage of a drug to the intended site in
the body, and to quickly obtain and then maintain the proper drug concentration (Sahil et al. 2011).
Oral ingestion has long been considered the most convenient, and therefore most commonly used,
drug delivery route (Thanoo, Sunny, and Jayakrishnan 1993). Within the set of oral drug delivery
systems, there are two subsets. These are single unit dosage forms (SUDFs), which are composed
of a single tablet or capsule, and multiple unit dosage forms (MUDFs). MUDFs include pellets,
mini-tablets, and granules and are distinguished by the fact that a single dose of the drug is
administered through multiple subunits, which each contain part of the drug dose. The entire dose
is composed of the sum of the drug contained in the subunits, and the functionality of the dose
relies on the functionality of the subunits (Lopes et al. 2006). This delivery system is especially
useful when the selected drugs have different mechanisms of action providing additive or
synergistic efficacy. It reduces the number of doses required of a particular agent (compared to
monotherapy) and has the potential to reduce side effects (Hadi, Rao, and Firangi 2012). In
addition, even though they may seem costlier than SUDFs, MUDFs actually lower costs, treatment
failure rate and case-fatality ratios. They also have the potential to reduce development of
resistance, raise colonic residence time, and provide more predictable gastric emptying, all of
which make the drugs more effective and reduce costs spent on new products for long-term therapy
(Dashora, Saraf, and Saraf 2008; Shivakumar, Suresh, and Desai 2007)
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Of the many forms of MUDFs, mini-tablets (also known as mini-matrices in the 1990s)
combine the many advantages of MUDFs with the economic benefits of SUDFs (Sujja-areevath
et al. 1996). Mini-tablets, are, as the name suggests, miniature tablets with a diameter of 2-5 mm
(Thomson et al. 2009). They can be filled into capsules or compacted together into larger tablets
that disintegrate and release the mini-tablets as MUDFs (Ishida et al. 2008; Lopes et al. 2006).
Mini-tablets are superior in some ways to granule and pellet forms because mini-tablet dosage
forms can be smaller (Ishida et al. 2008). There are several different ways that mini-tablets can be
formulated, including compressed, encapsulated coated, and compressed with a biphasic delivery
system (Hadi, Rao, and Firangi 2012). Chapter 2 describes a new way of formulating mini-tablets,
which was used in this study. Mini-tablets containing various amounts of ketoprofen (KPR) with
the taste-masking polymer Eudragit® E PO were successfully produced via a continuous process
of pelletization with an adapted pelletizer directly connected to a hot-melt extruder. As the molten
material emerges from the extruder, it is drawn from the die in rounded strands, run through a
cooling section which cools it to the softening point, then cut by a knife roller.
Pellets are a MUDF that is composed of free-flowing, spherical particles formed by the
agglomeration of fine granules of a drug compound together with excipients, and are usually
between 0.05 and 2.00 millimeters in diameter (Schilling et al. 2010). They are used for
compacting into tablets, filling capsules and molding by injection. Pellets are manufactured using
a variety of methods, including freeze palletization, cryopelletization, spray congealing, spray
drying, layering, compression, and extrusion/spheronization (Supriya, Rajni, and Rana 2012). A
recent method developed for the formation of pellets is HME together with a face-cut pelletizer, a
rotating knife on the extrusion die plate. With this method, the material is cut while still in a viscous
state, and because of surface tension, forms into spherical pellets (Roblegg et al. 2011). In chapter
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3, Pellets with satisfactory physico-mechanical characteristics were successfully prepared by melt
extrusion/face-cut pelletization using the optimized conditions, utilizing Soluplus® as a polymeric
carrier and carbamazepine (CBZ) as a model drug. The study discusses the development of novel,
“ready to fill” face-cut pellets as final/finished drug products using hot melt extrusion techniques.
Pharmaceutical powders are made up of very fine particles, the size of which is indicated
by the number consistent with the size of the mesh screen sieve used to sift them. The screen
number designates the number of openings per square inch. For example, a number 40 sieve has
40 openings per square inch of mesh. The particles which fit through these openings are “40 mesh”
size. Because disintegration is not necessary with powders, they act much more rapidly than minitablets and pellets. Chapter 4 presents research on the use of HME to form an extrudate strand that
was then milled, sieved, and filled into capsules. Suitable polymers and excipients (surfactants)
were chosen to combine with different poorly soluble drugs, in order to create pharmaceutical
powder systems with the required properties. Three poorly soluble drugs with varied melting
points are used to produce solid dispersion with Kollidon® VA 64 using Hot Melt Extrusion.
Different Lutrol® F grades surfactant (also called kolliphor® P grades) are added to the polymer
matrices to investigate their influence on the solubilty of the drugs.
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CHAPTER 2

PREPARATION AND EVALUATION OF HOT-MELT EXTRUDED PATIENTCENTRIC KETOPROFEN MINI-TABLETS
Abstract
The objective of the present study was to prepare taste-masked mini-tablets, which are easily
swallowed dosage forms primarily used by pediatric and geriatric patients. Hot-melt extrusion
technology was used to prepare mini-tablets of the bitter model drug ketoprofen (KPR). Eudragit®
E PO was used as a taste-masking polymer for the mini-tablets. Thermogravimetric analysis
(TGA) studies showed that the drug was thermally stable under the employed extrusion
parameters. Differential scanning calorimetry (DSC) and polarized light microscopy-hot stage
microscopy (PLM-HSM) studies confirmed that the binary mixtures were miscible under the
employed extrusion temperatures. The binary mixtures (10%–50% w/w) were blended and
extruded with a 5-mm strand die and cut into consistent mini-tablets by using an adapted
downstream pelletizer. In vitro release studies showed that drug release was less than 0.5% within
the first 2 min in simulated salivary fluid (pH 6.8) and more than 90% in the first 20 minutes in
simulated gastric fluid (pH 1.2). The results of the E-tongue analysis were well correlated with the
drug release results obtained for the mini-tablets in artificial saliva. SEM revealed no pores or
cracks on the surface of the mini-tablets, confirming that the mini-tablets were compact solids.
FTIR studies revealed that the carboxylic acid group in KPR had
8

anintermolecular interaction with the carrier. Chemical imaging confirmed the uniform
distribution of KPR inside the polymer matrices. These results confirmed the excellent suitability
of Eudragit® E PO for the preparation of novel pediatric and geriatric dosage forms aimed at
masking drug taste and improving patient compliance.

Keywords: Mini-tablets, Ketoprofen, Eudragit® E PO, Taste masking, Hot-melt extrusion, FTIR
chemical imaging

2.1 Introduction
The perceived taste of an oral dosage form is one of the primary factors influencing patient
compliance. Among the different taste sensations, bitterness is the most repellent (Joshi and
Petereit 2013). However, bitter tasting drugs represent a large portion of active pharmaceutical
ingredients (APIs). Therefore, masking the taste of bitter APIs can achieve improved patient
compliance, particularly in the case of pediatric patients, who are mostly unwilling to ingest bitter
tasting drugs, and geriatric patients, who may exhibit altered taste perception (Vummaneni and
Nagpal 2012).
To mask bitter tastes, the receptors of the taste buds must be sequestered from the bitter
APIs, which can be achieved by several different approaches. Bitter tastes can be masked by
applying a polymeric coating layer to create a physical barrier around the drug (Douroumis 2011;
Douroumis 2007) or by the use of complexing agents to form inclusion complexes or resonates
(Woertz et al. 2010). Recently, taste suppressant molecules have been used to block the gap
junction channels and hemichannels in taste bud cells to suppress taste (Sato et al. 2009; Lyall et
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al. 2010). However, there is a need for an approach to taste masking that offers robustness and
cost-effectiveness while being simple to scale up. Hot-melt extrusion (HME) satisfies these criteria
and can be used to efficiently produce taste-masked dosage forms.
HME is a continuous and solvent-free process for the manufacture of solid dispersions of
APIs for various applications (Repka et al. 2007a; Crowley, Zhang, Repka, Thumma, Upadhye,
Battu, et al. 2007). The HME technique can be used to enhance the solubility of drugs with poor
water solubility, as well as to manufacture modified/extended release and targeted drug delivery
systems. In recent years, HME has gained interest as a method for masking the taste of bitter APIs
by producing solid dispersions, which prevents direct contact of bitter drugs with the taste buds.
Using HME, extruded APIs can be molecularly dispersed in various polymer and/or lipid matrices
(Maniruzzaman et al. 2013; Maniruzzaman, Boateng, et al. 2012). A wide range of drug dosage
forms have been produced using HME (Breitenbach 2002; Mehuys, Remon, and Vervaet 2005;
Andrews et al. 2008). For example, HME has been used to prepare matrix mini-tablets for
ibuprofen using ethyl cellulose as a sustained release agent. To prepare the ibuprofen mini-tablets,
the researchers used a twin-screw extruder to prepare extrudates, which were manually cut into 2mm mini-matrices (De Brabander, Vervaet, and Remon 2003).
Mini-tablets are a compact dosage form with a diameter of 2–5 mm or smaller (Thomson
et al. 2009). The conventional method of preparing mini-tablets involves an ordinary reciprocating
rotary tableting machine (Lennartz and Mielck 1998). The mini-tablet dosage form offers several
advantages over conventional solid dosage forms such as tablet or capsules. Generally, minitablets are specifically designed for patients with difficulty in swallowing, in particular young
children (up to 10 years), geriatric patients, and patients with esophagitis. Mini-tablets are
particularly useful in pediatric patients under 10 years who may not have the skills to swallow
10

conventional dosage forms (Lou et al. 2013). In a previous study by Thomson et al. (2009), it was
shown that children aged between 2 and 6 years had high acceptance towards mini-tablets
(Thomson et al. 2009). Additionally, mini-tablets serve as a multi-particulate drug delivery system,
allowing fine-tuning of individual administration, reducing inter- and intra-subject variability, and
dose dumping while maintaining accurate dosing (De Brabander, Vervaet, and Remon 2003;
Stoltenberg and Breitkreutz 2011).
Content uniformity of mini-tablets is critical for accurate dosing. Fourier transform infrared
(FTIR) imaging is a well-established biomedical spectroscopy technique for visually estimating
content uniformity. FTIR imaging provides information regarding drug distribution, as well as
concentrations of chemical components, according to the unique spectroscopic signature of each
component. Analysis of FTIR images is based on selection of the unique spectroscopic
wavelength(s) from which the image was obtained. KPR and Eudragit® E PO were selected as
materials for the manufacture of mini-tablets in this study. KPR is a biopharmaceutical
classification system (BCS) class II drug for which dissolution is the rate-limiting step for oral
bioavailability. It is a bitter tasting, thermally stable drug that is practically insoluble in water at
20 °C and has low solubility in pH 1.2 buffer (0.06 μg/mL) (Mohammed et al. 2012). Furthermore,
it is an anionic drug, which could facilitate drug–polymer intermolecular interactions with
cationic-based polymers such as Eudragit® E PO. Eudragit® E PO is a dimethylaminoethyl
methacrylate-, butyl methacrylate-, and methyl methacrylate-based cationic copolymer that is
thermally stable. It is insoluble but swellable in saliva (pH 6.8); however, it is soluble in gastric
fluid at pH < 5.0 (Gryczke et al. 2011). All of the above characteristics make KPR and Eudragit®
E PO suitable choices as an API and taste-masking polymer, respectively, for this study.
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The objective of the present study was to prepare novel taste-masked mini-tablets of KPR
with the taste-masking carrier Eudragit® E PO by HME and to evaluate the effectiveness of the
taste masking with multiple in vitro methods. In addition, FTIR imaging was In addition, FTIR
imaging was utilized to visually approximate drug homogeneity

2.2 Materials and Methods
2.2.1 Materials
KPR USP was purchased from Letco Medical (Decatur, AL, USA). Eudragit ® E PO was
received as a gift sample from Evonik Degussa Corporation (Parsippany, NJ, USA). Calcium
chloride dihydrate, magnesium chloride hexahydrate, sodium chloride, potassium carbonate,
sodium phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, and all other
chemicals used in this study were of analytical grade and purchased from Fisher Scientific
(Norcross, GA, USA).
2.2.2 Methods
2.2.2.1 Thermogravimetric Analysis (TGA)
The thermal stability of the materials was studied using a PerkinElmer PyrisTM 1 TGA
system. The PyrisTM Manager software (PerkinElmer Life and Analytical Sciences, Waltham, MA,
USA) was used to operate the instrument and analyze the data. Under an inert nitrogen atmosphere
at a flow rate of 20 mL/min, 3–4 mg of the sample was weighed and heated from 25 °C to 220 °C
at 10 °C/min. Percent weight loss was plotted against temperature to determine the relationship
between weight loss and temperature.
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2.2.2.2 Differential Scanning Calorimetry (DSC)
A Perkin Elmer Diamond DSC (Perkin Elmer Life and Analytical Sciences, Waltham, MA,
USA) was used to study polymer-drug miscibility and to assess the physical state of KPR inside
the mini-tablets. Polymer-drug miscibility studies were performed on the physical binary mixtures
of Eudragit® E PO and KPR. Under an inert nitrogen atmosphere at a flow rate of 20 mL/min, 3–
4 mg of the sample was weighed in an aluminum pan and heated from 30 °C to 150 °C at a constant
heating rate of 10 °C/min. Endothermic onset and peak temperature of melting were calculated
from the obtained thermogram using Pyris™ Manager software. The crystallinity of KPR inside
the mini-tablets was evaluated similarly.
2.2.2.3 Hot Stage and Polarized Light Microscopy
The miscibility of the binary mixtures and changes in the crystalline shape of KPR and
Eudragit® E PO were evaluated using polarized-light hot-stage microscopy (HSM-PLM). A glass
slide with a small amount of the sample was inserted into a hot-stage system (FTIR 600, Linkam
Scientific Instruments, Surrey, UK). The sample was heated from 35 °C to 150 °C at a constant
rate of 10 °C/min. A camera-mounted optical microscope (Cary 620 IR, Agilent Technologies,
Santa Clara, CA, USA) equipped with a hot-stage and a crossed polarizer was used to capture
images at different stages of the transformation.
2.2.2.4 HME Processing
Ketoprofen (10%, 20%, 30%, 40%, and 50%) was blended with Eudragit® E PO using a
V-shell blender (Maxiblend®, GlobePharma, New Brunswick, NJ, USA) at 25 rpm for 10 min and
analyzed for drug content and blend uniformity. The drug-polymer blends were melt-extruded
using a co-rotating twin-screw extruder (Process 11 mm, ThermoScientific, Waltham, MA, USA)
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at processing temperatures of 100 to 120 °C, a screw speed of 100 rpm, and a feeding rate of 0.7
kg/h (Table 2-1). The die plate was attached to a circular nozzle insert (length: 15 mm; diameter:
5 mm) at a temperature range of 70 to 90 °C. Increasing the nozzle length and decreasing the die
temperature prevents the die swell phenomena associated with polymer melt and thus maintains
the strand shape (Gavis and Modan 1967; Hiemenz and Lodge 2007). A conveyor belt was used
to transfer the strands toward the cutting apparatus. The cutting length was set at 2 mm from the
pelletizer. The resulting strands were cut into mini-tablets using an adapted pelletizer (Type L001-9482, ThermoScientific, Stone, UK). HPLC analysis was used to evaluate post-extrusion drug
content and content uniformity.
Table 2-1: Ketoprofen formulations and hot-melt extrusion processing parameters.
Ketoprofen

Eudragit® E PO

Zone temp.

Die temp.

Screw speed

Feeding rate

% (w/w)

% (w/w)

(°C)

(°C)

(rpm)

(kg/h)

KPR1

10

90

120

90

KPR2

20

80

110

80

KPR3

30

70

110

80

100

0.7

KPR4

40

60

100

70

KPR5

50

50

100

70

Formulations
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2.2.2.5 Powder X-Ray Diffraction (PXRD)
PXRD was performed using a Bruker D8 Advance system with a Cu-source theta-2theta
diffractometer equipped with a Lynx-eye PSD detector. The generator was set at a voltage of 40
kV and a current of 30 mA. The samples were dispersed on a low-background Si sample holder
and compacted gently with the back of a metal spatula. The scan ran from 10°–40° with 2θ values
at 0.05° step size and 3 s/step.
2.2.2.6 HPLC Method
A Waters 600 binary pump, Waters 2489 UV/detector, and Waters 717 plus autosampler
(Waters Technologies Corporation, Milford, MA, USA) were the components of the HPLC
system. The stationary phase of the column was a Waters Symmetry shield C18 (250 × 4.6 mm, 5
μm particle size, reversed phase). The mobile phase was acetonitrile: 20 mmol phosphate buffer
(pH 4.0) (55:45, v/v) at a flow rate of 1 mL/min (Crowley et al. 2004). Ketoprofen was analyzed
at a wavelength of 256 nm. The powder of the physical mixtures was analyzed (n=5) by dissolving
weighed samples in 20 mL of acetonitrile. The contents of the mini-tablets were analyzed by
dissolving the mini-tablets (n=5) in the mobile phase and pre-filtering the samples through a 0.45μm membrane to extract the drug prior to HPLC injection. Similarly, the samples obtained from
the dissolution studies were filtered and injected at a volume of 20 μL. The data were acquired and
processed using the Waters Empower 3 software suite.
2.2.2.7 In Vitro Drug Release Studies
Taste-masking ability was assessed by measuring the in vitro release of KPR in 2
dissolution media to mimic in vivo salivary (pH 6.8) and gastric (pH 1.2) conditions. The tastemasking study was performed in 200 mL of simulated saliva (pH 6.8) with a USP Dissolution
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Apparatus I (Hanson SR8, Hanson Research, Chatsworth, CA, USA), maintained at 37 ± 0.5 °C
with a shaft rotation speed of 50 rpm (n = 3) and equipped with UV/Vis probes (Pion Rainbow®
instrument, Pion Inc., Billerica, MA, USA). Samples were collected every 5 sec for 2 min. The
composition of the simulated salivary media is shown in Table 2-2 (Azarmi, Roa, and Löbenberg
2007)
Table 2-2: Composition of simulated saliva (pH 6.8).
Salt

Concentration (g/l)

CaCl2·2H2O

0.228

MgCl2·6H2O

0.061

NaCl

1.017

K2CO3·1.5H2O

0.603

Na2HPO4·7H2O

0.204

NaH2PO4·H2O

0.273

For the in vitro release studies at gastric pH, a USP Dissolution Apparatus I was used with 900
mL of 0.1N HCl maintained at 37 ± 0.5 °C with a shaft rotation speed of 50 rpm (n = 3). Samples
were collected at 10, 20, 30, 45, 60, 90, and 120 min, filtered, and analyzed using a Waters HPLC–
UV system. Fresh dissolution medium was added to the dissolution vessel to replace the volume
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of the sample withdrawn at each time point. The cumulative of drug release was plotted against
time as a percentage.
2.2.2.8 Evaluation of Taste Using an E-Tongue
An Astree Liquid and Taste Analyzer with an electronic tongue (E-tongue) (Alfa MOS,
Toulouse, France) was used to evaluate the taste of the formulations. The Astree E-tongue system
was equipped with Alfa MOS sensor set #2 (pharmaceutical analysis), which was composed of 7
specific sensors (ZZ, AB, BA, BB, CA, DA, and JE) on a 48-position auto sampler (Alfa MOS,
Toulouse, France). The sensors on the E-tongue imitate the taste buds on the human tongue by
initiating changes in electrical potentials that can be compared to physiological action potentials
to allow estimation of taste. Mini-tablets approximately equivalent to 75 mg of KPR were added
to 50 mL of buffer solution (pH 6.8) and shaken at 50 rpm for 60 sec at 37 °C using a shaking bath
(Thermo Fisher Scientific, Stone, UK). The solution was filtered with a 0.45-micron syringe filter
(nylon membrane) into a 25-mL beaker (120 sec acquisition time, n = 5). The data generated using
the E-tongue were analyzed using principle component analysis with the AlphaSoft V12.3
software suite (Mathworks Inc., Natick, MA, USA).
2.2.2.9 Scanning Electron Microscopy
Scanning electron microscopy (SEM) was used to study the surface morphology of the
mini-tablets. Samples were mounted on adhesive carbon pads placed on aluminum stubs. A
Hummer® 6.2 sputtering system was used to coat the samples in gold in a high vacuum evaporator
(Anatech Ltd., Battle Creek, MI, USA). A scanning electron microscope operating at an
accelerating voltage of 5 kV was used for imaging (JEOL JSM-5600, JEOL Ltd., Tokyo, Japan).
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2.2.2.10 Chemical Imaging and FTIR Analysis
Mid-IR FTIR analysis was conducted in the spectral range of 4000–650 cm-1 using Cary
660 and Cary 620 FTIR Microscopes (Agilent Technologies, Santa Clara, CA, USA). The bench
was equipped with a MIRacle ATR (Pike Technologies, Fitchburg, WI, USA), that was fitted with
a single-bounce, diamond-coated ZnSe internal reflection element. Chemical imaging was
conducted using Cary 620 FTIR Microscope (Agilent Technologies, Santa Clara, CA, USA)
equipped with a 64 × 64 pixel focal plane array (FPA) with and without a germanium micro-ATR.
FTIR samples were studied before and after physical blending and melt extrusion to study
intermolecular interactions before and after applying high shear forces and elevated temperatures.
The chemical imaging samples were embedded in melted paraffin (Paraplast X-TRA®, SigmaAldrich, St. Louis, MO, USA) and reduced to 5-µm thickness using a microtome (Olympus America

Inc., Center Valley, PA, USA). Because the sample must be extremely thin to allow IR light to
penetrate it and reflect out, a microtome was used to produce thin sections of the pharmaceutical
extrudates for FTIR imaging. Chemical imaging was utilized to visually approximate drug
homogeneity and interactions.
2.2.2.11 Mini-tablet Properties
A Vanderkamp friabilator electrolab friability testing apparatus (Model 47-0100, VanKel
Industries, Edison, NJ, USA) was used to study friability and determine weight loss. Twenty minitablets from each batch were uniformly tumbled for 4 min at 25 rpm. The tested tablets were gently
tapped on ASTM #44 mesh and carefully collected. The weight loss was measured to determine
the friability of the mini-tablets.
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The hardness of the mini-tablets was measured using a VanKel hardness tester (Model VK
200, VanKel Industries, Edison, NJ, USA). Twenty mini-tablets from each batch were randomly
chosen for hardness testing. Each tablet was placed in the center of the apparatus against the face
plate of the sensing jaw. The force applied was continuously measured and recorded until initial
fracturing of the mini-tablet occurred.
2.2.2.12 Stability Studies
To study the stability of the micro-tablets, samples were stored in open glass vials for a
period of 3 months in ambient conditions (25 °C/60% relative humidity). After the 3-month
stability study, the samples were tested for physical and chemical stability utilizing DSC, PXRD,
and chemical assays. In addition, in vitro release studies were performed using the stored minitablets. The drug release profiles were compared to fresh samples by using similarity factor (f2
value)
2.3. Results and Discussion
2.3.1 Thermal Analysis
TGA studies showed that the drug was thermally stable. When heated from 25 °C to 220
°C at a heating rate of 10 °C/ min under an inert nitrogen atmosphere at a flow rate of 20 mL/min,
KPR began to degrade at approximately 200 °C (Fig. 2-1). Therefore, the temperatures in the
extrusion process were kept well below the degradation temperature of KPR to maintain its
stability in the binary mixtures.
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Fig. 2-1: TGA of Pure KPR and physical mixtures for KPR2 formulation.

In the DSC studies, a pure KPR melting endothermic peak was observed at 97 °C that was
not detected in the second round of heating, which confirmed the conversion of KPR into an
amorphous form. KPR was found to be miscible with Eudragit® E PO in all tested formulations
(Fig. 2-1). During the heating step, the endothermic melting peak and onset temperature were
lower than those of pure KPR for all formulations (Palmieri et al. 2002). The melting peak of KPR
was not identified in the final milled mini-tablets, confirming the amorphous state of the KPR
inside the mini-tablets (Fig. 2-2).
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Fig. 2-2: Thermogram of pure ketoprofen (KPR), physical mixtures, and milled extrudates
(0-day and 3-month stability samples) utilizing Eudragit® E PO matrices.

Polarized light can be used to detect the conversion of a crystalline form of an API into a
glassy/amorphous form under different temperatures on a hot-stage system (Lopes Jesus et al.
2010; Lakshman et al. 2008b). This technique was utilized in this study to investigate the changes
in the crystallinity of KPR under the temperatures applied in the extruder. All blended binary
mixtures were studied using HSM. Based on the HSM results, the binary mixture containing 40%
(w/w) KPR was chosen for further study due to the maximum birefringence obtained from its high
drug loading capacity. At the beginning of the heating cycle, KPR crystals were clearly visible,
whereas Eudragit® E PO particles were not visible, as they did not exhibit birefringence. At
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approximately 80 °C, the KPR crystals began solubilizing in the polymer matrix. However, the
KPR crystals that were not in contact with Eudragit® E PO were not solubilized. The complete
conversion of KPR to a glassy form was observed at 97 °C, at which temperature the drug formed
round-shaped droplets. During cooling, the glassy/amorphous KPR stayed in a miscible state and
did not recrystallize back into its original physical form. The binary mixtures were found to be
miscible with each other at the temperatures employed during extrusion (Fig. 2-3). All of the KPR–
Eudragit® E PO binary mixtures exhibited markedly similar results.

45°C

60° C

80° C

90° C

100° C

110° C

120° C

Cooling, 25° C

Fig. 2-3: HSM-PLM images of the ketoprofen (KPR4) formulation. The polymer matrix
began to solubilize the KPR crystals at around 80 °C. Complete conversion of crystalline
KPR into a molten form was observed at 97 °C. KPR in a glassy/amorphous form did not
recrystallize during the cooling step. The other KPR–Eudragit® E PO binary mixtures
exhibited similar results and are not presented here.
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2.3.2 HME Processing
Disconnection between the glass transition temperature (Tg) of Eudragit ® E PO and its
melt extrusion processing temperature has been reported in the literature. Sathagiri et al. (2012)
extruded Eudragit® E PO at a high temperature of 120 °C, even after adding 50% drug load
(Sathigari et al. 2012). Wu et al. (2003) found that the torque of the extruded formulation was an
important parameter to consider while setting the processing temperature (Wu and McGinity
2003). Pure Eudragit® E PO was extruded first at 120 °C to investigate its ability to form minitablets. The resulting mini-tablets from the polymer had sharp edges only. KPR, which melts at 97
°C, has been shown to provide a plasticizing effect in the melt extrudate (Crowley et al. 2004).
Therefore, in the presence of KPR, extrusion could be carried out at a lower temperature and a
higher screw speed. Measurements of drug loading demonstrated a significant effect of
temperature on the extrudability of the formulations. HME conditions, including barrel
temperature, screw speed, feeding rate, and die temperature were optimized to maximize the
integrity of the resulting strand. The shape of the strand was rounded due to the shape of the nozzle
used. After a short cooling phase on the conveyor belt, the strands entered the adapted cutting
pelletizer. The speed of the conveyor belt was slightly adjusted manually for each formulation to
yield 2 mm mini-tablets based on the extruder output. The resulting mini-tablets were 5 mm in
diameter and 2 mm in thickness (Fig. 2-4).
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a

b

c

Fig. 2-4: Images of the ketoprofen mini-tablets with a) 20%, b) 30%, and c) 40% drug
loading.
The addition of KPR smoothed the sharp edges of the mini-tablets. The edges of the mini-tablets
with 10% KPR were smoother than the pure Eudragit® E PO tablets, but required further
smoothing. The edges of the mini-tablets with 20%, 30%, and 40% KPR were relatively smooth
in comparison with those of the mini-tablets with a 10% drug load. Drug loading in the range from
20% to 40% resulted in clear and smooth KPR extrudate strands, which suggested the formation
of a single-phase system. On melting, KPR exhibits a tacky nature and cannot be extruded without
a polymer matrix (Crowley et al. 2004). At 50% drug loading, KPR-Eudragit® E PO began to form
elastic strands, which presented an obstacle for the pelletization process. In addition, due to the
relatively high drug loading of the 50% KPR mini-tablets, the mini-tablets stuck together and
exhibited surface deformation upon storage. Twenty mini-tablets from the various batches were
selected randomly for study of weight variation. The average weights of the KPR2, KPR3, and
KPR4 formulations were 63.02 ± 1.18, 61.65 ± 1.07, and 60.90 ± 1.11 mg, respectively. The
content of the mini-tablets was unaffected by drug loading. All of the mini-tablets possessed more
than 98.5 ± 0.5% drug content (Fig. 2-5) as well as content uniformities (<3% RSD) after extrusion.
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Fig. 2-5: Drug Content of ketoprofen mini-tablets.

2.3.3 PXRD

PXRD studies were performed to investigate the crystallinity and physical stability of KPR
in the milled mini-tablets. The XRD data of ketoprofen exhibited characteristic sharp peaks at 2θ
= 14.2, 18.4, and 22.9° (Crowley et al. 2004), which were not observed in the XRD data of the
milled extrudate (Fig. 2-6), suggesting that KPR was converted into an amorphous form postextrusion, as the exudates showed a halo pattern with no intense peaks. The conversion of KPR
into an amorphous form was confirmed by DSC and XRD.
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Fig. 2-6: Powder X-ray diffraction (PXRD) data for pure ketoprofen (KPR) and milled
extrudates (0-day and 3-month stability samples) utilizing Eudragit® E PO matrices.

2.3.4 In Vitro Drug Release Studies
Taste masking was assessed by measuring the in vitro release of KPR in 2 dissolution
media designed to mimic in vivo salivary (pH 6.8) and gastric (pH 1.2) conditions. In the simulated
salivary medium (pH 6.8), drug release was found to be less than 0.5% within the first 2 min for
all tested formulations (Fig. 2-7), which was attributed to the strong inhibition of drug release in
the oral cavity by Eudragit® E PO. In contrast, formulations KPR2, KPR3, and KPR4 showed
complete release of the drug within the first 20 min in the simulated gastric fluid medium (pH 1.2),
perhaps due to the rapid erosion of Eudragit® E PO at the relatively low pH of the medium. The
super-saturated solutions were stable during the 2 h dissolution interval (Fig. 2-8). All extruded
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formulations demonstrated significantly increased drug release in comparison with that of pure
KPR due to electrostatic interactions and salt formation between the -COOH groups of KPR and
the tertiary ammonium groups of Eudragit® E PO. The –COOH/ammonium group interaction can
be formed during the extrusion process and/or during drug release in 0.1N HCl. Quinteros et al.
(2008) and Kindermann et al. (2011) have previously demonstrated such molecular interactions
between acidic drugs and basic Eudragit® E PO (Quinteros et al. 2008; Kindermann et al. 2011).
The in vitro results in media mimicking artificial saliva and gastric fluid indicated that
incorporation into the KPR mini-tablets masked the taste of KPR in the oral cavity and facilitated
rapid drug release in the stomach, owing to the formation of a single-phase system, in which
electrostatic interactions and the formation of salts by acidic KPR and basic Eudragit® E PO were
of crucial importance.
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Fig. 2-7: In vitro release profiles of ketoprofen mini-tablets in simulated saliva (pH 6.8).
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Fig. 2-8: In vitro release profiles of ketoprofen (KPR) mini-tablets in 0.1N HCl.

2.3.5 Evaluation Using the E-tongue System
The taste-masking efficiency of the mini-tablets was evaluated by E-tongue analysis. The
selected data set was analyzed by PCA using 2 principal components (PC). PC1 explained 99.6%
of the variance in the data, whereas only 0.4% of the variance was explained by PC2. All
formulations were located very close to the buffer (pH 6.8 phosphate buffer) on the PC1 axis (Fig.
2-9/Table 2-3), indicating that the taste of each formulation, as measured by the E-tongue, was
very similar to that of the buffer solution and not to that of the bitter drug. The great distance
between pure KPR and the buffer on the PC1 plot clearly demonstrates the high degree of bitterness
of KPR. The small distances between the mini-tablet formulations could be attributed to the
differences in release rates during the first 60 sec, which correspond to the concentration
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differences. Indeed, these results were well correlated with the results for drug release from the
mini-tablets in artificial saliva, where the drug release for all mini-tablet formulations was less
than 0.5% in 120 sec (Fig. 2-6). The results for the KPR formulations, which were far from the
drug PC axis and near the buffer PC axis, indicated that using Eudragit® E PO in the extruded
formulation suppressed the bitter taste of KPR. This finding is important because it demonstrates
that mini-tablets prepared by the HME process reduce exposure of the drug surface area to the
taste buds.

Fig. 2-9: Principal Component Analysis chart for KPR2 (yellow), KPR3 (red) and KPR4 (blue).
Significant distance between the pure KPR to the formulations. Whereas, the distance between the
formulations to placebo (pH 6.8 phosphate buffer) is very close on PC1 axis.
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Table 2-3: E-Tongue distance of the mini-tablets from the buffer.
Formulation

Reference samples

Distance

Pattern discrimination index
(%)

Pure KPR

pH 6.8 buffer

3361

98.56

KPR2

pH 6.8 buffer

43

1.26

KPR3

pH 6.8 buffer

173

17.82

KPR4

pH 6.8 buffer

203

25.11

2.3.6 SEM
SEM was used to examine the surface morphology of the mini-tablets. SEM images were
taken of the cross-sections of the extrudate strands to allow examination of the mini-tablet surface.
The mini-tablets surfaces were found to be clear and homogenous at a range of drug loads and
processing temperatures. No pores or cracks were detected on the mini-tablet surface, confirming
that the mini-tablets were compact solids (Fig. 2-10).
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Fig. 2-10: SEM images of the surface of the ketoprofen (KPR) mini-tablets with a) 20%, b)
30%, and c) 40% drug loading.

2.3.7 Chemical Imaging and FTIR Analysis
Intermolecular forces between oppositely charged compounds, such as drugs and
polymers, result in masking of the bitter tastes of drugs (Gryczke et al. 2011). To assess this effect,
intermolecular interactions between KPR (an anionic drug) and Eudragit® E PO (a cationic
polymer) were investigated by FTIR. The infrared spectrum of KPR showed 2 carbonyl peaks
located at 1694 cm-1 and 1653 cm-1, which have been reported previously as a dimeric carboxylic
acid and a ketonic carbonyl group, respectively (Sancin et al. 1999; Mura et al. 1999). Extruded
formulations containing 40% w/w KPR were studied for clarity and showed stronger absorption
arising from a higher concentration of KPR, which correlated with a higher concentration of the
carbonyls under investigation. The positions of the carbonyls corresponding to the ester group in
the polymeric carrier and the ketone carbonyl in KPR, which were centered at 1724 cm-1 and 1653
cm-1, respectively, did not change from their pre-processing spectral positions (Kojima et al. 2012).
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However, the peak corresponding to the carboxylic acid carbonyl in KPR at 1694 cm -1 was not
distinguishable in the extruded samples, while it was clearly visible in the physical mixtures. It is
likely that the carboxylic acid group in KPR had a molecular interaction with the carrier, leading
to disruption of the carboxylic acid dimer in the crystalline KPR, which results in stretching of the
carboxylic acid bond and subsequently results in a somewhat distorted spectral appearance at
higher wavenumbers. The appearance of the carboxylic acid overlapped with, and thus was
indistinguishable from, the strong ester vibrations associated with the carrier (Fig. 2-11)

1724.075 0.210

0.5

1653.437 0.112

40 % KPR Milled

0.4

a

EXT.

0.3

0.2

Absorbance

0.1

1724.075 0.191

b

1694.846 0.074

40 % KPR PM.

1653.437 0.068

0.0
1694.846 0.230
-0.1

c

1653.437 0.213

Pure KPR.

-0.2

-0.3

d
-0.4

Pure E PO.

1724.075 0.200

-0.5

3800

3600

3400

3200

3000

2800

2600

2400
2200
Wavenumber

2000

1800

1600

1400

1200

1000

800

Fig. 2-11: FTIR analysis of pure ketoprofen (KPR), pure Eudragit® E PO, the physical
mixture of 40% KPR/Eudragit® E PO, and the milled extrudate containing 40%
KPR/Eudragit® E PO .
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The KPR carbonyl peak located at 1653 cm-1 was clearly visible and was chosen for
chemical imaging. Fig. 2-12 shows an infrared image of KPR in the mini-tablets taken at 5.5 µm
spatial resolution in transmission mode with a total field of view (FOV) of 300 × 300 µm. The
intensity of the chosen peak significantly affects the color represented in the images. The light blue
area represents low peak intensity, which correlates to a lower concentration of API relative to
areas of higher peak intensity, which are represented by orange to red coloration. As the
concentration of KPR inside the matrices increases, the intensity of the carbonyl peak at 1653 cm1

becomes higher and the colors in the images become intensified. Homogeneous distribution of

the drug in the mini-tablets was observed at different levels of drug loading. The chemical imaging
results were in agreement with the content uniformity test, which was performed by conventional
chemical analysis (Fig. 2-5).

a

b

c

Fig. 2-12: FTIR chemical images illustrating the distribution of ketoprofen (KPR) in the
mini-tablets. Homogeneous drug distribution was observed in the mini-tablets with a) 20%,
b) 30%, and c) 40% drug loading.
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2.3.8 Mini-tablet Properties
A friability testing apparatus was used to determine the weight loss of the mini-tablets (as
a percentage). In friability testing, no weight loss was observed and all tested mini-tablets were
found to be hard. These results were correlated well with the SEM findings, in which no pores and
cracks were detected on the surface of the mini-tablets. These findings confirm the excellent
mechanical properties of the mini-tablets prepared by the continuous HME process.
The hardness of the mini-tablets was measured using a hardness tester. The forces applied
to fracture the mini-tablets of KPR2, KPR3, and KPR4 were 82.67 ± 2.15 N, 79.63 ± 1.85 N, and
77.06 ± 1.46 N, respectively. The slight variation in the forces required to fracture the mini-tablets
was due to the differences in the percentage of KPR inside the mini-tablets. The addition of the
plasticizer (KPR) to the polymer matrix reduced the number of entanglements (Swallowe 1999),
disrupting the forces holding the chains together and decreasing the force required to fracture the
mini-tablets.
2.3.9 Stability Studies
Physical and chemical analyses were performed on the mini-tablets following storage at
ambient conditions (25 °C/60% relative humidity) in open glass vials for 3 months. The lack of a
crystalline melting peak in DSC (Fig. 2-1) and the characteristic peaks in PXRD studies (Fig. 2-5)
for all formulations after 3 months of storage confirmed that the amorphous form of the drug was
maintained. Moreover, drug release was not affected by 3 months of storage (Fig. 2-13). The drug
release profiles were assessed by similarity factor (f2 value). If the similarity factor is between 50
and 100, that would suggest that two release profiles are similar. The f2 value of KPR2, KPR3 and
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KPR4 were 64, 57 and 56 respectively, suggesting that dissolution profiles are similar. The drug
exhibited excellent stability inside the matrix over the storage period of 3 months. This result
corroborates the previous findings, which indicated that significant drug-polymer interactions
enhance the stability of the prepared formulations.
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Fig. 2-13: In vitro release profiles of ketoprofen (KPR) mini-tablets in 0.1N HCl after 3
months of storage in open vials at ambient conditions (25 °C/60% relative humidity).

2.4. Conclusion
Mini-tablets containing various amounts of KPR with the taste-masking polymer Eudragit®
E PO were successfully produced via a continuous process of pelletization with an adapted
pelletizer directly connected to a hot-melt extruder. The manufactured mini-tablets were compact,
with smooth surfaces and excellent uniformity. KPR bitterness was reduced due to the formation
of a physical barrier layer of the polymer around the drug. Intermolecular interactions between

35

oppositely charged compounds may have reduced the bitter taste of the drug and increased the
stability of the formulation. These results confirmed the promise of Eudragit® E PO in the
preparation of novel pediatric and geriatric mini-tablet dosage formulations as a means of masking
drug taste and increasing patient compliance.
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CHAPTER 3
OPTIMIZATION OF HOT MELT EXTRUSION PARAMETERS FOR SPHERICITY
AND HARDNESS ON POLYMERIC FACE-CUT PELLETS
Abstract
The aim of this study was to formulate face-cut, melt extruded pellets and to optimize hot melt
process parameters to obtain maximized sphericity and hardness by utilizing Soluplus® as a
polymeric carrier and carbamazepine (CBZ) as a model drug. Thermal gravimetric analysis (TGA)
was used to detect thermal stability of CBZ. The Box-Behnken design for response surface
methodology was developed using three factors, processing temperature (℃), feeding rate (%),
and screw speed (rpm), which resulted in 17 experimental runs. The influence of these factors on
pellet sphericity and mechanical characteristics was assessed and evaluated for each experimental
run. Pellets with optimal sphericity and mechanical properties were chosen for further
characterization. This included differential scanning calorimetry, drug release, hardness friability
index (HFI), flowability, bulk density, tapped density, Carr’s index, and fourier transform infrared
radiation (FTIR) spectroscopy. TGA data showed no drug degradation upon heating to 190⁰C. Hot
melt extrusion (HME) processing conditions were found to have a significant effect on the pellet
shape and hardness profile. Pellets with maximum sphericity and hardness exhibited no crystalline
peak after extrusion. The rate of drug release was affected mainly by pellet size, where smaller
pellets released the drug faster. All optimized formulations were found to be of superior hardness
and not friable. The flow properties of optimized pellets
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were excellent with high bulk and tapped density. FTIR Analysis showed the formation of
hydrogen bonding between the -N-H group of CBZ with the C=O in Soluplus®.

Keywords: Sphericity, Hardness, Hot-melt extrusion, Face-Cut Pellets Box-Behnken design,
carbamazepine

3-1 Introduction

Hot-melt extrusion (HME) is a continuous manufacturing process in which an extrudate is
obtained by forcing the active drug and excipients through a die under controlled conditions,
including temperature, mixing, feed-rate, and pressure (Abrahamsson et al. 1996). This process is
used to achieve solid dispersions or solid solutions, which may have the potential to increase
solubility, dissolution rate, and the bioavailability of poorly water soluble active pharmaceutical
ingredients (APIs) (Crowley, Zhang, Repka, Thumma, Upadhye, Battu, et al. 2007; Hulsmann et
al. 2000; Leuner and Dressman 2000a). HME overcomes some of the limitations of traditional
manufacturing techniques such as spray drying or freeze drying, including solvent usage and
multiple processing steps. However, during the formulation of HME products, there are several
obstacles that need to be overcome. First, the influence of the variable HME process parameters
on the processing material must be optimized based on the final goal (Breitenbach 2002; Repka et
al. 2007a). Second, identification of the combination of API, carrier, and additives is necessary for
achievement of the desired final dosage form. Third, the downstream processing needs to be
optimized based on the intended final dosage form (Daniel Treffer 2013). Commonly, extrudates
are milled and used to fill capsules, compressed into tablets, or shaped using a downstream-adapted
pelletizer. In this study, the strand of a certain material composition is shaped into spherical pellets
using a face-cut pelletizer to avoid the downstream processing and overcome the above limitation.
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Face–cut pelletizing is an innovative technology where the hot, molten strand is cut directly
into small pellets by a rotating knife immediately after exiting the die. The cutting takes place
above the softening point, and the pellets are transported to the cyclone by a vacuum where viscous
forces, like surface tension, act as a driving force that allows the pellets to contract and become
spherical (Daniel Treffer 2013; Treffer et al. 2014). Extrusion–spheronization is the typical way
of producing spherical pellets (Lustig-Gustafsson et al. 1999; Vervaet, Baert, and Remon 1995;
Young, Koleng, and McGinity 2002). After extrusion, the extrudate is cut or broken into
cylindrical pieces and spheronized in an extra, discontinuous step. During spheronization,
irregularly shaped material is heated, with or without a heated spheronizer, to a softening
temperature to make rounded pellets. Further spheronizing steps are unnecessary when using facecut pelletization. Combining HME with face-cut pelletization offers an outstanding advantage,
because spherical pellets can be produced using a single continuous step.

Numerous studies have reported the production of nearly spherical pellets by face-cut
pelletization and evaluated the influence of formulation composition and process parameters on
the morphology of pellets. Roblegg et al. (2011) reported the use of calcium stearate (CaSt) as a
thermoplastic excipient for preparation of face-cut pellets, which are cooled externally (Roblegg
et al. 2011). Bialleck and Rein (2011) have reported the development of starch-based face-cut
pellets containing different APIs (Bialleck and Rein 2011). The two studies have found that the
morphology of pellets depends on the composition of formulations and process parameters. In this
study, we used a novel air-cooled face-cut pelletizer connected to a pipe (tube), where the air
pushed pellets through it into the cyclone. The synergistic effect of viscous forces, like surface
tension, with high rotation speed in the cyclone resulted in superior spherical shape.
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In order for pellets to be accepted as a dosage form and administered to patients, they
should have certain physico-mechanical characteristics, such as sphericity, good flow property,
ease of dosing, compact structure, and smooth surface with high bulk density (Manivannan et al.
2010). Sphericity is one of the important measurements for assessing quality of pellets. Highly
spherical pellets flow easily, which is considered ideal for automated processes (tableting, capsule
filling, and packaging), where maintaining exact dosing is required (Heng, Wong, and Chan 2000).
It is also necessary for pellets to possess sufficient mechanical strength to withstand the mechanical
forces associated with the manufacturing process (Jawahar and Anilbhai 2012). The aim of this
study was to formulate face-cut, melt extruded pellets and to optimize hot melt process parameters
on pellets to obtain maximized sphericity and hardness utilizing Soluplus® as a polymeric carrier
and carbamazepine (CBZ) as a model drug.

3. 2 Materials and Methods
3.2.1 Materials
CBZ was purchased from Afine Chemicals Limited (Zhejiang, China). Polyvinyl
caprolactam–polyvinyl acetate–polyethylene glycol graft copolymer (PVCL–PVAc–PEG,
Soluplus®) were kindly donated by BASF SE (Ludwigshafen, Germany). All other chemicals used
were of analytical grade and obtained from either Fisher Scientific (Waltham, MA, USA) or
Spectrum Chemicals (New Brunswick, NJ, USA).
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3.2.2 Methods
3.2.2.1 Thermal gravimetric analysis
The thermal stability of the physical mixture and CBZ was detected at the employed
extrusion temperatures using a Perkin Elmer Pyris 1 thermogravimetric analyzer (TGA) (Waltham,
MA, USA). The Pyris manager software (Perkin Elmer Life and Analytical Sciences) was used for
running the instrument and analyzing the data. Three to 4 mg of physical mixture was weighed
and heated from 20 °C to 250 °C at 10 °C/min under a controlled atmosphere of nitrogen. Percent
weight loss was plotted against temperature to determine weight loss.
3.2.2.2 Hot melt process
The polymer was screened using a USP #35 mesh screen. The subjected polymer was preplasticized with propylene glycol (3%) to prevent sudden stop of the extruder due to high torque
at low temperature with high screw speed. CBZ was blended with Soluplus® at 10% drug loading
using a V-shell blender. The blend was extruded using a co-rotating twin-screw hot melt extruder
connected to an air-cooled face-cut pelletizer. HME was performed at different levels of
processing temperatures, feeding rates, and screw speeds to optimize the ranges that yielded
pellets. The die plate was coupled with a nozzle and attached to the face-cut pelletizer by screws.
The face-cut pelletizer had a blower unit that generated air that pushed the pellets cut at the die
plate into the cyclone through a pipe. The face cutter speed was kept constant at 70 rpm. Pellets
started rotating at the cyclone under high speed which resulted in a high amount of air, and falling
down into a basket.
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3.2.2.3 Design of experiment
The Box-Behnken design for response surface methodology was developed using Design
Expert® 8.0.6 (Stat-Ease, Inc., Minneapolis, MN, USA). The optimized ranges and level of the
variables are shown in Table 3-1.

Table 3-1: The three factors of Box-Behnken design.
Variables

Symbol

Levels
-1

0

+1

Processing Temp (℃)

A:A

120

135

150

Feeding rate (%)

B:B

3

5

7

Screw speed (rpm)

C:C

100

150

200

This design requires an experimental number of runs calculated as follows:
𝑁 = 𝑘 2 + 𝑘 + 𝑐𝑝

(1)

Where, k is the factor number, 3 in this case, and cp is the number of replications at the center
point, 5 in this case. The design resulted in 17 experimental runs, as shown in Table 2. The three
dimensions of the cube correspond to three factors, processing temperature (℃), feeding rate (%),
and screw speed (rpm). The center point is a white circle to illustrate that this particular set of
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levels was replicated five times in this design, allowing for strong estimation of variance (Fig. 31).

Fig. 3-1: A three-dimensional representation in space of 3 Levels, 3 Factors Box-Behnken
Design.

3.2.2.4 Differential scanning calorimetry
DSC was utilized to analyze the samples. Three-5 mg of milled pellets was analyzed at 10
°C/min heating rate between 30 °C and 200 °C. Pyris™ manager software was used to calculate
peak temperature at melting.
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3.2.2.5 High-performance liquid chromatography (HPLC) method
The drug content was determined by a Waters HPLC consisting of Waters 600 binary
pump, Waters 2489 UV detector, and Waters 717 plus auto sampler (Waters Technologies
Corporation, Miliford, MA, USA). The stationary phase of the column was a Waters Symmetry
shield C18, 250 × 4.6 mm, 5 μm particle size, reverse phase. The mobile phase was methanol,
water, and acetic acid (34:65:1 % v/v) at a flow rate of 1 ml/min, and the ultraviolet (UV) detector
was set at 285 nm wavelength (Alshahrani et al. 2015). Drug content uniformity of pellets was
analyzed by dissolving the pellets in mobile phase and pre-filtering through a 0.45-μm filter and
injected at volume of 20 μl. Similarly, samples obtained from dissolution studies were filtered and
injected. All studies were performed as replicates of five.
3.2.2.6 Determination of sphericity and pellets size
In order to determine the sphericity of the pellet, the shape and the area of pellets were
investigated by optical microscopic image analysis (Abbaspour, Sadeghi, and Garekani 2005).
Thirty pellets were selected randomly, and images were taken by Nikon Eclipse E600 Pol
microscope equipped with a Nikon DS-Fi 1 camera (Tokyo, Japan). The images were taken under
a top source of light on a black background to reduce the shadow. Image analysis software was
used to calculate area and perimeter. Circulatory factor (S) was calculated using the equation:
S = 12.56 (A) / P2

(2)

Where, A is the area (cm2) and p is the perimeter (cm).
Aspect ratio (AR) of optimized formulations was calculated from the following equation:
AR = dmax / dmin

(3)
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Where, dmax and dmin are the maximum and minimum Feret diameters measured by the software,
respectively.
The microscope was fitted with ocular and stage micrometers, and the size of the optimized
formulation was calculated as an average of 30 pellets.
3.2.2.7 Determination of hardness
Pellet Hardness was measured using a Tablet Hardness Tester Vankel hardness tester
(Model VK 200, Vankel Industries, Cary, NC, USA). Thirty pellets were selected randomly, and
each pellet was placed in the center against the face plate of the sensing jaw. The force applied
was continuously measured and recorded until the initial fracture of the pellet was detected and
confirmed.
3.2.2.8 Physical characterization data of optimized pellets
3.2.2.8.1 Hardness friability index (HFI)
HFI was measured using Electrolab Friability testing apparatus (Vankel Vanderkamp
Friabilator). Thirty g of the optimized pellets were uniformly tumbled for 20 min at 25 rpm. The
tested pellets were gently tapped on ASTM # 40 mesh and were carefully collected, and the loss
in weight was measured. HFI (%) was calculated using Equation 3:
% HFI = (Fa / Fb) × 100

(4)

Where, Fb and Fa are the weights of the pellet before and after friability test.
3.2.2.8.2 Flowability
To determine the flow property of the pellets, flow rate was evaluated by using Flowdex®
(Hanson Research Corporation, Chatsworth, CA, USA). The flowability apparatus was equipped
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with 20 mm orifice. Thirty g of the pellets were weighed and filled into a funnel fixed on a clamp.
The time was recorded from starting the pellets flow through orifice until finish in a beaker placed
on electronic balance. The flow rate was expressed as gm.s-1 (n=3).

3.2.2.8.3 Bulk density, tapped density, and Carr’s index
The bulk density was calculated as the ratio of weight to the occupied volume. The
optimized pellets were poured into a previously weighed graduated glass cylinder, and the weight
to occupy the volume was determined. Bulk density was calculated as M/Vi where M is weighed
mass and Vi is the initial unsettled apparent volume (n=3). Tapped density was calculated as M/Vf
where M is weighed mass and Vf is the final tapped volume (n=3). Carr’s (Compressibility) index
was measured according to following equation:
𝐶𝑎𝑟𝑟’𝑠 𝐼𝑛𝑑𝑒𝑥 = (𝑡𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 – 𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦) × 100 / 𝑡𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦

(5)

3.2.2.9 FTIR analysis
Mid-IR analysis was conducted in the spectral range of 4,000–900 cm-1 using Cary 660
and Cary 620 FTIR Microscopes (Agilent Technologies, Santa Clara, CA, USA). The bench was
equipped with a MIRacle ATR (Pike Technologies, Fitchburg, WI, USA) that was fitted with a
single-bounce, diamond-coated ZnSe internal reflection element. FTIR samples were studied
before and after physical blending and melt extrusion to study intermolecular interactions before
and after applying high shear forces and elevated temperatures.
3.3 Results and Discussion
3.3.1 Thermogravimetric analysis
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The thermal stability of the drug and physical mixture at employed extrusion temperatures
was evaluated. The data showed no drug degradation when heated to 190⁰C (Fig. 3-2).
Formulations were processed below this temperature to maintain the thermal stability of the drug.

Fig. 3-2: Thermograms of pure carbamazepine (CBZ) and physical mixture with 10% drug
loading

3.3.2 Screening HME ranges
HME was performed to optimize the maximum and minimum ranges of processing
parameters that yielded pellets with acceptable mean size. The minimum screw speed to maintain
a continuous process was found to be 100 rpm. The extrusion temperature greatly influences the
rheological properties of a molten formulation, which dictates the pelletization characteristics of
the formulation tested. The temperature range was found to be between 120 and 150⁰C. The
extruder barrels stopped below 120⁰C due to high torque, and the extrudate became more molten
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above 150⁰C, leading to loss of pelletization characteristics. The feed rate affected the size of the
pellets, the screw speed, and extrusion temperatures. A feeding rate of 7% was found to be the
maximum feeding rate that resulted in a mean pellet size at around 2 mm.
3.3.3 Design of experiment
The influence of extrusion temperature, feeding rate, and screw speed were evaluated in a
quantitative way using response surface curves. The proposed second-degree polynomial was
fitted to the data presented in Table 3-2 using multiple linear regressions to determine the optimum
HME conditions that resulted in maximum sphericity and hardness. The predicted levels of
sphericity (R1) and hardness (R2) are given in Table 3-2 and were calculated using Equation (5)
and (6), respectively.
𝑅1 = 0.871 + 0.117 ∗ 𝐴 + 0.0355 ∗ 𝐵 − 0.0015 ∗ 𝐶 − 0.01975 ∗ 𝐴𝐵 + 0.01175 ∗
𝐴𝐶 + 0.02325 ∗ 𝐵𝐶 − 0.058375 ∗ 𝐴2 − 0.010375 ∗ 𝐵2 − 0.004375 ∗ 𝐶2

(5)

𝑅2 = 3.98 + 0.27 ∗ 𝐴 + 0.98 ∗ 𝐵 − 0.22 ∗ 𝐶 + 0.14 ∗ 𝐴𝐵 − 0.14 ∗ 𝐴𝐶 + 0.37 ∗
𝐵𝐶 − 0.43 𝐴2 − 0.51 ∗ 𝐵2 − 0.10 ∗ 𝐶2

(6)
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Table 3-2: Three factors of Box-Behnken design with experimental as well as predicted
responses of independent variable
Runs

A:A

B:B

C: C

Observed

Predicted

Observed

Predicted

Sphericity

Sphericity

Hardness

Hardness

F1

135

3

100

R1
0.834

R1
0.845

R2 (kPa)
2.88

R2 (kPa)
2.98

F2

135

7

100

0.861

0.870

4.15

4.20

F3

135

5

150

0.871

0.871

3.98

3.98

F4

120

3

150

0.634

0.630

2.05

1.94

F5

120

7

150

0.742

0.740

3.67

3.61

F6

150

5

200

0.928

0.936

3.37

3.36

F7

150

7

150

0.931

0.935

4.32

4.43

F8

135

5

150

0.871

0.871

3.98

3.98

F9

120

5

100

0.712

0.704

3.26

3.27

F10

120

5

200

0.665

0.678

2.93

3.09

F11

135

5

150

0.871

0.871

3.98

3.98

F12

135

7

200

0.925

0.913

4.60

4.49

F13

135

3

200

0.805

0.796

1.86

1.80

F14

150

3

150

0.902

0.903

2.15

2.21

F15

150

5

100

0.928

0.915

4.25

4.08

F16

135

5

150

0.871

0.871

3.98

3.98

F17

135

5

150

0.871

0.871

3.98

3..98
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The significance of the fit of the second-order polynomial for the R1 and R2 was observed
by carrying out analysis of variance (ANOVA), with results shown in Tables 3-3, 3-4, and 3-5.
The squared correlation coefficient (R2) of the model was 0.9935 and 0.9899 for R1 and
R2, respectively (Table 3-3), meaning that 99.35% (R1) and 98.99% (R2) of variation was
explained by the model and only 0.65% and 1.01% of variation was a result of chance. This
indicated that the model adequately represented the real relationship between the factors. The
coefficient of variation (C.V.) obtained was 1.37% and 3.67% for R1 and R2, respectively. The
low value of C.V. indicated a high reliability of the experiment (DC 2013; Mason LR 2003).
Adequate precision measured the signal to noise ratio, where ratio greater than 4 (R1, 34.868 and
R2, 27.307) is desirable (Kaur et al. 2012).

Table 3-3: Statistical information (ANOVA)
Source

R1 value

R2 value

R-squared

0.9935

0.9899

Adjusted R-squared

0.9851

0.9770

Standard deviation

0.011

0.13

C.V %

1.37

3.67

Adeq. precision

34.868

27.307
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From results obtained in Table 3-4 for sphericity (R1), values of ‘‘Prob. > F’’ less than
0.05 indicated that the model terms were significant. Values greater than 0.10 indicated that the
model terms were not significant. A model F-value of 118.59 and a very low probability value
(Prob > F) less than 0.05 implied a significant model fit. From the regression model, the model
terms A, B, and A2 were significant model terms. The terms AB and BC were also significant
model terms. This indicated that there was an interaction between extrusion temperature and
feeding rate as well as between feeding rate and screw speed. However, the interaction between
extrusion temperature and screw speed had no significant effect on pellet sphericity.
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Table 3-4: Analysis of variance (ANOVA) for quadratic model of sphericity (R1)
Source

Sum of Squares

df

Mean Square

F Value

p-value [Prob > F]

Model

0.14

9

0.015

118.59

< 0.0001

A-A

0.11

1

0.11

839.17

< 0.0001

B-B

0.010

1

0.010

77.26

< 0.0001

C-C

1.800E-005

1

1.800E-005

0.14

0.7213

AB

1.560E-003

1

1.560E-003

11.96

0.0106

AC

5.522E-004

1

5.522E-004

4.23

0.0787

BC

2.162E-003

1

2.162E-003

16.57

0.0047

A2

0.014

1

0.014

109.95

< 0.0001

B2

4.532E-004

1

4.532E-004

3.47

0.1047

C2

8.059E-005

1

8.059E-005

0.62

0.4577

Residual

9.135E-004

7

1.305E-004

Lack of Fit

9.135E-004

3

3.045E-004

Pure Error

0.000

4

0.000

Cor Total

0.14

16
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significant

By increasing the extrusion temperature, the pellets that reached the cyclone were still soft
and viscous during rotation, which helped them contract and become more spherical. Viscous
forces like surface tension acted as a driving force and worked synergistically with the high
rotation speed inside the cyclone. In contrast, lower extrusion temperature did not allow the pellets
to reach the cyclone while they were in the soft and viscous form. The air that pushed them through
the pipe caused them not to be as soft as pellets extruded at higher temperatures. The same principle
applied to the feeding rate, as a high feeding rate brought more material to the cyclone. More
material could retain heat and remained soft, whereas a small amount of material cooled quickly.
Increasing the feeding rate improved the sphericity even at a lower extrusion temperature.
Increasing the extrusion temperature along with feeding rate resulted in high spherical pellets. The
interaction between screw speed and feeding rate significantly affected pellet sphericity.
Increasing the screw speed resulted in high shear and energy input, which enhanced the
temperature of the material inside the extruder. Therefore, by increasing the feeding rate along
with screw speed, the high amount of material that reserved more heat gained more heat from the
high shearing force, making the pellets softer when they reach the cyclone. The longer they are
still soft inside the cyclone, the greater likelihood the pellets will contract and become more
spherical.
Regarding hardness (R2) (Table 3-5), a value of ‘‘Prob. > F’’ less than 0.05 indicated the
model term was significant, whereas a value greater than 0.10 indicated the model term was not
significant. A model F-value of 76.60 and a very low probability value [(Prob > F) less than 0.05]
implied a significant model fit. From the regression model, the model terms A, B, C, A 2 and B2
were significant model terms. Another significant model term was BC, where the interaction
between feeding rate and screw speed significantly influenced pellet hardness.
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Table 3-5: Analysis of variance (ANOVA) for quadratic model of Hardness (R2)
Source

Sum of Squares

df

Mean Square

F Value

p-value [Prob > F]

Model

11.33

9

1.26

76.60

< 0.0001

A-A

0.59

1

0.59

36.14

0.0005

B-B

7.60

1

7.60

462.71

< 0.0001

C-C

0.40

1

0.40

24.10

0.0017

AB

0.076

1

0.076

4.60

0.0691

AC

0.076

1

0.076

4.60

0.0691

BC

0.54

1

0.54

32.87

0.0007

A2

0.77

1

0.77

46.55

0.0002

B2

1.08

1

1.08

65.66

< 0.0001

C2

0.043

1

0.043

2.63

0.1491

Residual

0.12

7

0.016

Lack of

0.12

3

0.038

Pure Error 0.000

4

0.000

Cor Total 11.45

16

Fit
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significant

The increase in sphericity was accompanied by an increase in hardness. The shape and size
of the pellets (diameter and thickness) revealed how a given hot melt processing parameter affected
pellet hardness. When comparing non-spherical pellets to highly spherical pellets, the highly
spherical pellets offered a smaller area to the sensing jaw of the hardness tester. Thus, increasing
the load per unit area delayed fracture, which further resulted in increased hardness. Increasing the
extrusion temperature lowered the melt viscosity, which made the material flow faster inside the
extruder and promoted die swell phenomena at the die plate, leading to larger pellets (Gavis and
Modan 1967; Hiemenz and Lodge 2007). In addition, increasing the temperature produced softer
extrudate, which was exposed to sudden cooling. The sudden cooling caused rapid contraction of
polymer subunits, which increased the entanglement of chains and decreased porosity, resulting in
greater resistance to fracture. Increasing the feeding rate increased the size of pellets significantly.
Increasing the output from the die plate led to larger pellets, which provided more resistance for
pellets to break. Extrusion temperature and feeding rate were found to significantly affect pellet
hardness. The increase in shearing force resulted in the generation of more heat, thus decreasing
the melt viscosity. Material with low melt viscosity flowed faster, which increased the amount of
output and, hence, the size of pellets. The interaction between feeding rate and screw speed resulted
in increased pellet hardness. Since the feeding rate highly affected pellet hardness, the high
shearing force enhances the melt flowability inside the extruder.

55

3.3.4 Optimization of HME conditions
In order to optimize the influence of different processing parameters on the sphericity and
hardness of produced pellets, we generated response surface plots using the regression model. The
three-dimensional (3D) plots were obtained by keeping one factor constant at the center point and
changing the others within the giving range. The resulting response surface plots revealed the
influence of processing parameters on pellet sphericity and hardness. Figs. 3-3 to 3-5 show the
response surface and corresponding contour plots for the optimization of pellet sphericity.
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Fig. 3-3 shows the response surface and corresponding contour plots for pellets sphericity
as a function of processing temperatures and feeding rate. An increase in the processing
temperature with an accompanying increase in feeding rate resulted in an increase in pellets
sphericity.
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Fig. 3-3: The response surface (A) and corresponding contour (B) plots for pellets’
sphericity as a function of processing temperatures (°C) and feeding rate (%).
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Fig. 3-4 shows the response surface and corresponding contour plots for pellets sphericity
as a function of processing temperatures and screw speed. An increase in the processing
temperature with an accompanying increase in screw speed resulted in an increase in pellets
sphericity.
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Fig. 3-4: The response surface (A) and corresponding contour (B) plots for pellets’
sphericity as a function of processing temperatures (°C) and screw speed (rpm).
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Fig. 3-5 shows the response surface and corresponding contour plots for pellet sphericity
as a function of feeding rate and screw speed. It shows that the pellet sphericity was improved by
increasing feeding rate and screw speed
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Fig. 3-5: The response surface (A) and corresponding contour (B) plots for pellets’
sphericity as a function of feeding rate (%) and screw speed (rpm).
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Figs. 3-6 to 3-8 show the response surface and corresponding contour plots for the
optimization of pellets hardness. Fig. 3-6 shows the response surface and corresponding contour
plots for pellet hardness as a function of processing temperature and feeding rate. An increase in
the feeding rate with an accompanying increase in processing temperature resulted in an increase
in pellet hardness.
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Fig. 3-6: The response surface (A) and corresponding contour (B) plots for pellets’
hardness as a function of processing temperatures (°C) and feeding rate (%).
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Fig. 3-7 shows the response surface and corresponding contour plots for pellet hardness as
a function of extrusion temperature and screw speed. The interaction between extrusion
temperature and screw speed had no significant effect on pellet hardness.
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Fig. 3-7: The response surface (A) and corresponding contour (B) plots for pellets’
hardness as a function of processing temperatures (°C) and screw speed (rpm).
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Fig. 3-8 shows the response surface and corresponding contour plots for pellet hardness as
a function of feeding rate and screw speed. An increase in the feeding rate with an accompanying
increase in screw speed resulted in an increase in pellet hardness.
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Fig. 3-8: The response surface (A) and corresponding contour (B) plots for pellets’
hardness as a function of feeding rate (%) screw speed (rpm).
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From the obtained results, Formulations F6, F7, and F15 had the maximum sphericity and hardness
compared to other formulations, such as F4 (Fig. 3-9).
A)
00F6

F7

F15

F7

F15

F4

B)
F6

F4

Fig. 3-9: A) Microscopic and B) digital images of optimized formulations and negative
control (F4)

Formulation F12 had maximum sphericity and hardness, but the average size of the F12
formulation was outside the acceptable pellet size range (0.5-2 mm) (Table 3-6). To confirm the
sphericity test finding, aspect ratio was measured for all optimized formulations. The aspect ratio
of optimized pellets formulations were found to be within the acceptable range, which is from 11.2 (Table 3-6).
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3.3.5 Drug content analysis
The content uniformity of the pellets was affected by the different processing parameters.
The drug content of F12 formulation was 78.81 ± 4.58%. Hence, at a lower processing temperature
(135) and higher feeding rate (7%), Soluplus® exhibited higher viscosity, and drug diffusion in the
polymer became more limited. This resulted in relatively poor mixing inside the extruder. The
drug content of F6, F7, and F15 formulations was 105.82 ± 1.0%, 98.93 ± 3.34%, and 98.61±
2.46%, respectively (Table 3-6).
Based on sphericity, hardness, average size, and drug content analysis, formulations F6, F7, and
F15 were the optimized formulations and chosen for further studies.

Table 3-6: The mean size and drug content of pellets with maximum sphericity and hardness
Formulations

Average Size

Aspect Ratio

(mm)

Drug Content
(%)

F6

1.62

1.026

105.82

F7

2.06

1.028

98.93

F15

1.85

1.037

98.61
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3.3.6 Differential scanning calorimetry
The DSC thermograms showed that pure CBZ was characterized by a single, sharp melting
endotherm peak at 192.9 °C (Fig. 3-10). The optimized extruded pellets showed no thermal peak
for CBZ. This indicated that CBZ was solubilized and converted into the amorphous form in the
polymer melt after extrusion.

Fig. 3-10: DSC thermogram of pure Carbamazepine (CBZ) and extrudate utilizing
Soluplus® matrices.

3.3.7 Drug release study
CBZ is an antiepileptic drug with poor water solubility (17.7 mg/L at 25°C, log P value of
2.45) (Bertilsson and Tomson 1986). It is considered a Class II drug according to the
Biopharmaceutical Classification System (BCS), which is characterized by low water solubility
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and high permeability. Soluplus® is an amphiphilic polymer that forms micelles in solution, and
hence, can work as a solubilizing agent for poorly water-soluble drugs. Soluplus® can successfully
enhance the solubility of CBZ at 10% drug loading and lower (Hardung H 2010). Drug release
from all of the optimized pellet formulations demonstrated greater dissolution than the pure drug.
The drug release from the F6, F7, and F15 formulations was more than 80% within 90 minutes.
(Fig. 3-11). The release rate from the F6 formulation was faster than the F7 and F15 formulations.
This was attributed to the size of the pellets, where F6 pellets were smaller in size than F7 and
F15. All pellet release profiles exhibited sustained release behavior. The spherical pellets have a
smaller surface area that comes in contact with dissolution medium than the non-spherical pellets.
Therefore, spherical pellets take longer to release the drug than non-spherical pellets.

120

% of CBZ release

100
80
F7

60

F15

40

F6

20
0
0

20

40

60

80

100

120

Time (minutes)
Fig. 3-11: Carbamazepine dissolution profiles (Type II) in 900 ml of water at 100 rpm
(n=3).
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3.3.8 Physical Characterization Data of the Optimized Pellets
3.3.8.1 Hardness friability index (HFI)
A friability testing apparatus was used to determine weight loss of the pellets (as a
percentage). In friability testing, no weight loss was observed, and all tested pellets were found to
be of superior hardness (Table 3-7). These findings confirmed the excellent mechanical properties
of pellets prepared by the continuous HME process.
3.3.8.2 Flowability
Highly spherical pellets flow easily, which is considered ideal for further processing. From
data presented in Table 3-7, the F6 pellet formulation flowed more easily than F7 and F17. This
could be attributed to the fact that small size pellets start to flow more easily from the orifice than
large size pellets.
3.3.8.3 Bulk density, tapped density and Carr’s index
In the pharmaceutics field, Carr’s index is used as another indicator of flowability. A Carr’s
index more than 25 indicates poor flow properties, and less than 15 indicates good flow properties
(Bouffard et al. 2007; Shah, Tawakkul, and Khan 2008). Highly spherical pellets occupy less
volume, and there is not much difference between the value of bulk and tapped density. In Table
3-7, the values of bulk and tapped density for all optimized formulations were very close. The
Carr’s index of all optimized pellet formulations was less than 15.
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Table 3-7: Physical characterization data of the optimized pellets.
HFI

Bulk density

Tapped density

Carr’s index

(gm.s-1)

(%)

(gm/cc)

(gm/cc)

(%)

F6

5.61

0.17

0.767

0.826

7.14

F7

5.35

0.16

0.773

0.830

7.37

F15

5.42

0 .16

0.771

0.842

8.43

Formulation Flowability

3.3.9 FTIR analysis
Intermolecular interactions between CBZ and Soluplus® were investigated by FTIR. In Fig.
3-12, propylene glycol exhibited a broad peak at around 3336 cm-1, which corresponded to O-H
functional group. Soluplus® exhibited a characteristic peak at 1729 and 1631 cm-1, which belonged
to C=O vibration (Deshmukh et al. 2011). The infrared spectrum of CBZ showed a characteristic
peak of crystal form III located at 3466 cm-1, which belonged to –N-H vibration and has been
reported previously (Grzesiak et al. 2003). This peak appeared in the physical mixture, suggesting
no intermolecular interaction prior to extrusion. After extrusion, the peak belonging to –N-H
stretching vibration of CBZ disappeared, and only peaks of Soluplus® were clearly seen, consistent
with the prior literature (Djuris et al. 2013). The absence of the N-H stretch peak indicated potential
hydrogen bonding formed between the N-H group of CBZ with the C=O in Soluplus®. The
formation of hydrogen bonds most likely acts synergistically with the solubilization effect of
Soluplus® to enhance the solubility and stability of CBZ in pellet formulations.
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Fig. 3-12: FTIR analysis of pure propylene glycol, pure Soluplus®, pure CBZ, physical
mixture of 10% CBZ/ Soluplus® E PO, and the milled extrudate containing 10% CBZ/
Soluplus®

3.4 Conclusion
The Box-Behnken experimental design was successfully utilized for the optimization of
HME connected to a face-cut pelletizer, required only 17 experiments. Pellets with satisfactory
physico-mechanical characteristics were successfully prepared by melt extrusion/face-cut
pelletization using the optimized conditions. The present study discusses the development of
novel, “ready to fill” face-cut pellets as final/finished drug products using HME techniques. These
studies may be beneficial for optimizing the manufacture of other types of dosage forms. Changing
face cutter speed is a point of interest for future work.
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CHAPTER 4
INFLUENCE OF LUTROL® F GRADES (POLOXAMER) ON SOLUBILITY OF HOT
MELT EXTRUDED KOLLIDON® VA64 DRUG-INCORPORATED MATRICES
Abstract
The objective of this study was to assess the potential of Lutrol® F grades as polymeric surfactants
for solubility enhancement of Kollidon®VA64 drug matrices produced by Hot Melt Extrusion
(HME). Three poorly soluble drugs (fenofibrate, felodipine and griseofulvin) which have different
melting points, and varying grades of Lutrol® F (also called Kolliphor® P grades) were added into
the HME systems to investigate their influence on the drug-incorporated matrices. Two grades of
Lutrols, Lutrol® F 68 (Kolliphor®P 188) and Lutrol® F 127 (Kolliphor®P 407) were studied as
polymeric solubilizers. Each drug was mixed with Kollidon®VA64, with or without Lutrol®F
(alone or in combination) at predetermined amounts which resulted in 24 formulations. Each blend
was melt extruded at the same extrusion conditions. Differential Scanning Calorimetry and Powder
X-ray diffraction studies suggested formation of amorphous solid dispersion for all extruded
formulation. Dissolution studies revealed that the extrudates with Lutrol® F grades exhibited faster
and higher release compared to formulations without Lutrol® F grades. Formulations with high
drug loading, which did not include Lutrol® F grades, demonstrated low drug release profiles,
when compared with the same formulations containing Lutrol® F grades. Micrometrics Studies
revealed that when extruded at the same extrusion temperature, formulations with the low-meltingpoint drug (fenofibrate) and
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that contain Lutrol® F grades have smaller specific surface areas than formulations with no Lutrol®
F grades. FTIR studies indicates that a stronger hydrogen bond has occurred between the (–NH)
of Felodipine and the (C=O) of the pyrrolidone group in Kollidon® VA 64, whereas fenofibrate
and griseofulvin did not appear to interact with the polymer matrices.

Keywords: Lutrol® F, Kollidon®VA 64, Hot-melt extrusion, Fenofibrate, Felodipine, Griseofulvin

4.1 Introduction
Hot-melt extrusion has gathered an attention in the field of pharmaceutical industry due to
its advantages. The considerable advantages of HME over other traditional processing techniques
are being a solvent free and continuous process requiring fewer processing steps (Crowley, Zhang,
Repka, Thumma, Upadhye, Battu, et al. 2007). Excipients such as plasticizers, surfactants, and
antioxidants can be used if needed (Repka et al. 2007a). The major candidates for HME are the
poorly water soluble APIs which are brought up by combinatorial chemistry and high throughput
screening (Repka et al. 2008).
Poorly water soluble APIs are classified according to the Biopharmaceutical Classification
System (BCS). Solid drugs with BCS II and IV class are considered to have poor water solubility,
and consequently a low bioavailability (Amidon et al. 1995). Currently, the poorly water soluble
APIs represent 40% of marketed drugs and 80%–90% of drug candidates in the R&D pipeline
(Babu and Ashwini 2011). Melt extrusion has been successfully applied to enhance solubility of
poorly soluble drugs by developing solid dispersion system (SDSs) (Feng et al. 2012; Lakshman
et al. 2008a). A drug/polymer system is called an SDS when the drug is molecularly dissolved at
the polymer matrix to form a single phase system (Amin 2013). SDSs work by converting the drug
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from the crystalline form into the amorphous form, or by the formation of a molecular
dispersion/solid solution. The higher free energy of the amorphous form helps in increasing the
solubility and dissolution rate (Vasconcelos, Sarmento, and Costa 2007). Incorporation of
polymeric surfactants like Lutrol® F grades in HME process were found to improve the solubility
and dissolution rate of poorly water soluble APIs (Fule and Amin 2014).
In this study, solid dispersions with Kollidon® VA 64 were produced via Hot Melt
Extrusion. Three poorly soluble drugs (fenofibrate, felodipine and griseofulvin) which have
different melting points, and varying grades of Lutrol® F (also called Kolliphor® P grades) were
added into the HME systems to investigate their influence on the drug-incorporated matrices.
Fenofibrate (FEN) is an antilipidemic drug which is used to reduce cholesterol levels in
patients suffering from hyperlipidemia who are at high risk of cardiovascular diseases (Wysocki
et al. 2004). It is a lipophilic drug (log P = 5.24) (Vogt, Kunath, and Dressman 2008) with a poor
aqueous solubility less than 0.29 mg/L at 37 °C (Buch et al. 2010) and a melting point at 80°C.
Felodipine (FEL) is a long-acting 1,4-dihydropyridine-calcium channel blocker which is used in
the treatment of hypertension (Sajkov et al. 1997). It is a lipophilic drug (log P = 4.8) (Nielsen et
al. 2001) with a poor aqueous solubility less than 1mg/L at 37 °C and a melting point at 145°C.
Griseofulvin (GSF) is an antifungal drug which is widely used for the treatment of Mycotic
infections on skin, hair, and nails (Gupta et al. 2004). It is a lipophilic drug (log P = 2.2) (Nielsen
et al. 2001) with a poor water solubility less than 9.05 mg/L at 37 °C and a melting point at 220°C.
Kollidon VA64 is vinyl pyrrolidone – vinyl acetate copolymer which is soluble in water. Lutrol®
F68 and Lutrol® F127 are block-copolymers, neutral surfactants which work as solubilizing agents
and plasticizers in solid dispersion systems (Chen et al. 2004; S Ali 2010). Lutrol® F68 has melting
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point (52∘C) and lower molecular weight than Lutrol® F127 which melts at 56∘C (BASF 2010).
The main properties of Lutrol® are presented in Table 4-1 (Jannin, Pochard, and Chambin 2006).
The objective of this study was to assess the potential of Lutrol® F grades as polymeric
surfactants for solubility enhancement of Kollidon®VA64 drug matrices produced by Hot Melt
Extrusion (HME).
Table 4-1: Properties of Lutrol® F68 and Lutrol® F127
Molecular weight % of polyethylene–glycol polymers

HLB

(g/mol)

Melting point
(◦C)

Lutrol® F68

8436

81.8 ± 1.9

29

52

Lutrol® F127

12330

73.2 ± 1.7

18–23

53–57

4.2 Materials and Method:
4.2.1 Material
High purity fenofibrate, felodipine, and griseofulvin were purchased from Ria International
LLC (East Hanover, NJ). Kollidon® VA64, Lutrol® F 68 and Lutrol® F 127 were donated by BASF
Chemical Co. (Ludwigshafen, Germany). All the organic solvents and water were high
performance liquid chromatography (HPLC) grade.
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4.2.2 Method
4.2.2.1 Hot-melt extrusion
Three poorly water-soluble drugs (BCS Class II APIs), fenofibrate, felodipine and
griseofulvin , were selected based on their differences in melting points. Two grades of Lutrols,
Lutrol® F 68 (Kolliphor®P 188) and Lutrol® F 127 (Kolliphor®P 407) were studied as polymeric
solubilizers. Each drug was mixed with Kollidon®VA64, with or without Lutrol®F (alone or in
combination) at predetermined amounts (Table 4-2) which resulted in 24 formulations. The
physical mixtures were initially sieved with USP 60 mesh and mixed in a V-cone blender
(MaxiBlendTM, GlobePharma, North Brunswick, NJ, USA) at 50 rpm for 15 min. Each blend was
evaluated for blend uniformity using HPLC and then melt extruded using a twin-screw extruder
(Process 11, ThermoScientific).
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Table 4-2: Extrudate compositions and processing parameters
Zone temp.
FEN, FEL & GSF

Lutrol® F 68

Lutrol® F 127

Kollidon® VA 64

10 %

-

-

90.0%

2.5%

-

87.5%

-

2.5%

87.5%

1.25%

1.25%

87.5%

-

-

70.0%

7.5%

-

62.5%

-

7.5%

62.5%

3.75%

3.75%

62.5%

30%

FEN, FEL & GSF

All zones 130 ℃

Screw speed
rpm

100

4.2.2.2 Differential Scanning Calorimetry
A Perkin Elmer Hyper Differential scanning calorimeter (DSC) (Perkin Elmer life and
analytical sciences, 710 Bridgeport Ave., Connecticut, USA) was utilized to detect the physical
state of FEN, FEL & GSF inside the milled extrudate. 3-4 mg of the samples was weighed in an
aluminum pan and the heating rate was 10 ˚C/min. The melting points (Tm) were calculated from
the obtained thermogram by Pyris™ manager software. Crystallinity of different drugs inside
different matrices was also evaluated similarly.
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4.2.2.3 Powder X-ray diffraction (PXRD)
PXRD studies were performed on a powder X-ray diffraction apparatus (Bruker AXS,
Madison, WI) using CuKα radiation at 40 mA and 40 kV. The samples of interest were analyzed
in the diffraction angles range of 5–40° (2θ) at a scan rate of 2°/min.
4.2.2.4 HPLC Methods
A Waters 600 binary pump, Waters 2489 UV/detector and Waters 717 plus autosampler
(Waters Technologies Corporation, 34 Maple St, Miliford MA0157) were the components of the
HPLC. The stationary phase of the column was a Waters Symmetry shield C18, 250X4.6mm, 5μm
particle size reverse phase. The mobile phases were 85:15(% v/v) acetonitrile-phosphoric acid in
water (pH = 2.5), 85:15(% v/v) methanol-water and 80:20(% v/v) acetonitrile-water for FEN, FEL
& GSF, respectively. The mobile phase flow rate was maintained at 1.0mL/min. FEN, FEL & GSF
were extracted at 286 nm, 238 nm and 295 nm wavelengths, respectively. The powder of physical
mixtures and milled extrudate were analyzed by dissolving weighed samples in 20 ml of respective
mobile phases and filtering through a 0.45 μm membrane to extract the drug prior to HPLC
injection. All studies were performed as replicates of three and injected at 20 μl volume.
4.2.2.5 In Vitro Dissolution Studies
Milled extrudates containing FEN, FEL & GSF equivalent to 40 mg, 5 mg & 30 mg were
filled into capsules and subjected to dissolution studies using a Hanson SR8-Plus dissolution test
system. The dissolution medium of FEN was 1000 ml 0.025 M SLS which was maintained at 37
± 0.5° C, and operated at 75 RPM paddle speed. The dissolution medium of FEL was 900 ml water
which was maintained at 37 ± 0.5° C, and operated at 100 RPM paddle speed. The dissolution
medium of GSF was 1000 ml water which was maintained at 37 ± 0.5° C, and operated at 50 RPM
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paddle speed. 1.5 mL samples were collected precisely at pre-determined intervals and replaced
with equal amounts of fresh dissolution medium. The withdrawn samples were immediately
filtered through 13 mm PTFE membrane filters (Whatman, Piscataway, NJ) with a pore size of 0.2
µm and analyzed using the same method mentioned in the section of HPLC Methods. A modelindependent, f2 similarity factor values were calculated to compare the dissolution profiles (Kim
et al. 2012)
4.2.2.6 Micromeritics Studies
The influence of extrusion temperature on the resulting extrudates from each of the
fenofibrate formulations were compared in terms of surface area using Micromeritics instrument
(Micromeritics Gemini III 3275, BET Surface Area Analyzer). The specific surface area was
calculated by the Brunauer, Emmett, and Teller (BET) theory using nitrogen gas as adsorbate.
2.2.7 FTIR Analysis
Mid-IR FTIR analysis was conducted in the spectral range of 4000–650 cm-1 using Cary
660 and Cary 620 FTIR Microscopes (Agilent Technologies, Santa Clara, CA, USA). The bench
was equipped with a MIRacle ATR (Pike Technologies, Fitchburg, WI, USA), that was fitted with
a single-bounce, diamond-coated ZnSe internal reflection element. FTIR samples were studied
before and after physical blending and melt extrusion to study intermolecular interactions before
and after applying high shear forces and elevated temperatures.
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4.3 Results and Discussion:
4.3.1 Differential Scanning Calorimetry
The DSC thermograms of different APIs along with solid dispersions were reported in Fig.
4-1, 4-2 and 4-3. The pure drugs had a distinct melting peak at 80, 145, and 220℃, respectively,
whereas endothermic peaks disappeared in all of the melt extrudates suggesting formation of
amorphous solid dispersion.

Fig. 4-1: DSC thermograms of pure Fenofibrate (FEB) and extrudate utilizing Kollidon ®
VA 64 matrices
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Fig. 4-2: DSC thermograms of pure Felodipine (FEL) and extrudate utilizing Kollidon® VA
64 matrices.

Fig. 4-3: DSC thermograms of pure Griseofulvin (GSF) and extrudate utilizing Kollidon®
VA 64 matrices
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4.3.2 Powder X-ray diffraction (PXRD)
XRD data exhibited sharp peaks for the pure drugs, while the milled exrtudates showed a
halo effect with no intense peaks (Fig. 4-4, 4-5 and 4-6). The results confirm the DSC finding that
all drugs were transferred to amorphous state during the extrusion process.
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Fig. 4-4: PXRD of pure Fenofibrate (FEN) and extrudate utilizing Kollidon® VA 64
matrices
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Fig. 4-5: PXRD of pure Felodipine (FEL) and extrudate utilizing Kollidon® VA 64 matrices
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Fig. 4-6: PXRD of pure Griseofulvin (GSF) and extrudate utilizing Kollidon® VA 64
matrices
81

4.3.3 Effect of Lutrol F Grades
Lutrol® F68 and Lutrol® F127 (poloxamers) exist individually as monomolecular micelles.
They form multimolecular aggregates when their concentration in the system increases. Lutrols
are block-copolymers consisting of Polypropylene oxide (PPO) and polyethylene oxide (PEO)
units. Polypropylene oxide (PPO) usually forms central hydrophobic cores, wherein methyl groups
interact via Van der Wall’s forces with the substance undergoing solubilization. Polyethylene
oxide (PEO) block causes water solubility due to the hydrogen bonding interactions of ether
oxygen with water molecules. As result of these interactions, Lutrols are readily soluble in polar
and nonpolar solvents (BASF 2010; Jijun et al. 2010). Lutrol® F68 is composed of more
hydrophilic polyethylene oxide (PEO) than Lutrol® F127 (Table 4-1). This leads to a higher HLB
value and as a result, it has great tendency to solubilize in water. On the other hand, Lutrol® F127
is less water-soluble and more swellable in water than Lutrol® F68. The swelling of hydrophilic
polymers is well known to allow more drug release from dense polymer matrices by creating a
porous matrix (Martin et al. 2002; Miyagawa et al. 1996)
4.3.4 In Vitro Dissolution Studies
The DSC and PXRD studies confirmed the amorphous state of the different drugs in all
formulations. The amorphous state of the drugs offers a lower thermodynamic barrier to
dissolution media where the drug is molecularly dispersed in the polymer. The amorphous drugs
are structurally disordered with no lattice energy which needs to be overcome. This results in an
enhanced solubility and dissolution rate (Jung et al. 1999; Leuner and Dressman 2000b). The
significant differences in the dissolution profiles between the matrices are due to the difference in
the solubility and dissolution natures of the polymer as well as surfactants in the dissolution media.
Dissolution of the different drugs in Kollidon® VA 64 alone is governed by the polymer itself,
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whereas in the case of Kollidon® VA 64-surfactant systems, the dissolution rate is governed by
solubilization of the polymer to create a hydrotropic environment for the poorly water soluble
drugs (Fule and Amin 2014). Dissolution studies revealed that the extrudates with Lutrol® F grades
exhibited faster and higher releases than without Lutrol® F grades, leaving the drug as a fine
precipitate. The significant improvement of dissolution rate is attributed to drug-polymer
molecular intermixing at a microlevel. The drug loading has a clear effect on the release profile,
and supersaturation was generated in all formulations. The higher drug loaded formulations with
Lutrol® F grades had lower drug release profiles compared to lower drug loaded formulations. The
percentage of drug contents of all formulations was found in the range of 95-105%. Extrusion at
same temperature wasn’t found to affect the content of different drugs with varied melting points
(Fig. 4-7, 4-8 and 4-9)
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Fig. 4-7: Drug Content analysis of FEN extrudate (n=3)
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Fig. 4-8: Drug Content analysis of FEL extrudate (n=3)
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Fig. 4-9: Drug Content analysis of GSF extrudate (n=3)
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For FEN formulations, the total percentage of 40 mg of pure FEN released in 2 hours did
not exceed 16%, while after extrusion, all extruded formulations released all drug content within
120 minutes. The 10% drug loaded formulations showed a faster release rate than 30% drug loaded
formulations (Fig. 4-10a.). Adding Lutrol® F grades to the formulation resulted in a slower drug
release rate which can be attributed to the plasticization effect of Lutrol® F grades. Extruding at
the same extrusion temperature makes formulations with Lutrol® F in them more molten than those
without, so upon cooling at room temperature, the pores of the more molten formulations shrink
and as result, a smaller surface area is obtained. This is confirmed by studying the surface areas of
FEN formulations using a micrometric approach. The results of the specific surface area
measurements indicate that formulations with no Lutrol® F have higher surface areas than
formulations with Lutrol®. A 10% drug loaded formulation with no Lutrol® had a specific surface
area of 0.1750±0.0029 m2/g. The release rate of the 10% drug loaded formulations with different
Lutrol® F grades showed different behaviors. The release rate and the corresponding surface area
for 10% drug loaded FEN formulations were as follow:
Formulation with Lutrol® F 68 > formulation with Lutrol® F 127 > formulation with Lutrol® F 68
and Lutrol® F 127 with a specific surface area of 0.1382±0.0035 m2/g, 0.1267±0.0037 m2/g and
0.1157±0.0055 m2/g, respectively.
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Fig. 4-10a: 10% Fenofibrate (FEB) dissolution profiles (Type II) in 1000 ml of 0.025 M SLS
at 75 rpm (n=3).

The order of release rate of 30% drug loaded formulations was the same as for 10% drug
loaded formulations but release rate for all formulations is slower than 10% drug loaded
formulations (Fig. 4-10b.). This is due to increasing the lipophilic part in the formulations. The
specific surface area of the 30% formulation with no Lutrol® F (1743±.0014 m2/g) was very close
to that for the 10% formulation with no Lutrol® F. This indicates that the plasticization effect from
Lutrol® F was stronger than the plasticization effect of the drug itself. It makes the formulation
more molten, and therefore makes the specific surface area smaller.
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The release rates and corresponding surface areas for 30% drug loaded FEN formulations
were as follow:
Formulation with Lutrol® F 68 > formulation with Lutrol® F 127 > formulation with Lutrol® F 68
and Lutrol F 127 with a specific surface area of 0.1239±0.0042 m2/g, 0.1183±0.0032 m2/g and
0.1120±0.0037 m2/g, respectively.
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Fig. 4-10b: 10% Fenofibrate (FEB) dissolution profiles (Type II) in 1000 ml of 0.025 M SLS
at 75 rpm (n=3).

For FEL formulations, the total percent of 5mg of pure FEL released in 2 hours did not
exceed 1.6% in water media, while after extrusion, all extruded formulation released a larger
percentage of the drug into the media within 120 minutes. A 10% drug loaded formulation with
Lutrol® F 68 showed the maximum release, compared to all other formulations (Fig. 4-11a.). This
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is can be attributed to the fact that Lutrol® F 68 has a higher HLB value and as a result, it has
greater tendency to solubilize the drug in water. The formulation with combinations of Lutrol® F
grades 68 and 127 showed more drug release in the medium than the formulation with only Lutrol
F 127. This clearly shows that the amount of Lutrol® F 68 is the leading factor in solubilizing the
drug. Formulations with no Lutrol® had the lowest release amount. The polymer did not help to
increase the solubility of the 10% drug loaded formation in non-sink conditions without need for
surfactants. The same release behavior of 10% drug loaded formulations was obtained with 30%
drug loaded formulations (Fig. 4-11b.), but the increased drug loading has the clear effect of the
decreasing amount of drug released in the media.
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Fig. 4-11a: 10% Felodipine (FEL) dissolution profiles (Type II) in 900 ml of water at 100
rpm (n=3).

88

100

PURE FELODIPINE

Drug release (%)

80

30% FEOLDIPINE,
70% KOLL. VA 64

60
30% FELODIPINE,
7.5% LUTROL F 68

40
30% FELODIPINE,
7.5% LUTROL F 127

20
0
0

20

40

60

80

100

120

30% FELODIPINE,
3.75% LUTROL F 68 &
3.75% LUTROL F 127

Time (minutes)
Fig. 4-11b: 30% Felodipine (FEL) dissolution profiles (Type II) in 900 ml of water at 100
rpm (n=3).

For GSF formulations, the total percentage of 30mg of pure GSF released in 2 hours did not exceed
16% in water media. After extrusion, all extruded formulation release a greater percentage of the
drug into the media within 120 minutes. The release of the 10% drug loaded GSF formulations
showed no significant differences between all formulations with or without Lutrol® F grades (Fig.
4-12a.). When the drug load was increased to 30%, the formulations with Lutrol® F, regardless of
grade, released approximately equal amounts into the media within a 2 hour time period (Fig. 412b.). On other hand, the formulation with no Lutrol® F showed an even lower release rate and
amount. Therefore, the polymer alone did not help in increasing the solubility of 30% drug GSF
formulations in non-sink condition without the need for surfactants.
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Fig. 4-12a: 10% Griseofulvin (GSF) dissolution profiles (Type II) in 900 ml of water at 50
rpm (n=3).
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Fig. 12b: 30% Griseofulvin (GSF) dissolution profiles (Type II) in 900 ml of water at 50
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4.3.5 Dissolution profiles comparison using similarity factor
Release kinetics were compared using similarity factors (f2) to assess the similarity of
release profiles between Lutrol® F included formulations and Lutrol® F non-included formulations.
If the similarity factor is between 50 and 100, that suggests that two release profiles are similar
(Alshehri et al. 2015). For 10% FEN drug loaded formulations, f2 values for formulations
containing Lutrol® F 68, Lutrol® F 127 and a combination of the two are 66, 43 and 24, respectively
using a formulation containing 10% drug with no Lutrol® F as a reference product. The release
profile for formulation containing Lutrol® F 68 is considered similar, while the others are not
similar. For 30% FEN drug loaded formulations, f2 values for formulation containing Lutrol ® F
68, Lutrol® F 127 and the combination are 26, 26 and 28, respectively using formulation containing
30% drug with no Lutrol® F as a reference product. It indicates that dissolution profiles are not
similar, because the incorporation of Lutrol® F grades in matrices containing 30% drug load
enhanced the saturation solubility in sink condition over the formulation containing 30% FEN with
no Lutrol® F grades in it.
For 10% FEL drug loaded formulation, f2 values for formulations containing Lutrol® F 68,
Lutrol® F 127 and the combination are 12, 24 and 18, respectively using the formulation containing
10% drug with no Lutrol® F as a reference product. For 30% FEL drug loaded formulations, f2
values for formulations containing Lutrol® F 68, Lutrol® F 127 and the combination are 1, 11 and
4, respectively using a formulation containing 30% drug with no Lutrol® F as a reference product.
From the above results for 10% and 30% drug loaded FEL formulations, it is clearly seen that
dissolution profiles are not similar and incorporation of Lutrol® F grades helped to dramatically
enhance the saturation solubility of FEL in non-sink conditions.
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For 10% GSF drug loaded formulations, f2 values for formulation containing Lutrol® F
68,Lutrol® F 127 and the combination are 50, 57 and 49, respectively, using the 10% GSF
formulation with no Lutrol® F as a reference product. The dissolution profiles are considered
similar. Non-sink conditions do not show discrimination in the release behavior between the
different formulations. For 30% GSF drug loaded formulations, f2 values for formulations
containing Lutrol® F 68, Lutrol® F 127 and the combination are 19, 23 and 21, respectively, using
the 30% drug formulation with no Lutrol® F as a reference product. It is clearly seen that by
increasing the amount of drug in the matrix, the content of the polymer decreased and dissimilarity
between dissolution profiles are observed. Overall, In-non sink condition, the saturation solubility
of GSF decreased as the drug load increased.
4.3.6 FTIR Analysis
Fourier transform infrared spectroscopy is one of the most widely used techniques to
characterize the intermolecular interactions in SDSs (Van Eerdenbrugh and Taylor 2011).
Extruded formulations containing 30% w/w FEN, FEL and GSF were studied for clarity and
showed stronger absorption arising from a higher concentration of each drug. The Lutrol® F 68
showed characteristic peaks at 2,886 and 1,102 cm-1 arising from stretching of C–H, and C–O
groups (Xie et al. 2009). Kollidon® VA 64 spectra exhibits two stretching peaks of (-COO) at 1734
cm-1 which belongs to vinyl acetate monomer (Ajay et al. 2012) and at 1666 cm-1 which belongs
to the vinyl pyrrolidone monomer (Liu et al. 2013). Pure FEN spectrum (Fig. 4-13.) shows two
absorption peaks at 1727 and 1649 cm–1 which belong to stretching vibration of two carbonyl
groups of ester and ketone, respectively (Nassar et al. 2011). Neither peaks of FEN, polymer or
surfactant have disappeared, switched or broadened. Fenofibrate did not appear to interact with the
polymer matrices.
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Fig. 4-13: FTIR analysis of pure Lutrol® F 68, pure Kollidon® VA 64, Pure Fenofibrate and
the milled extrudate containing 30% Fenofibrae

Felodipine was reported to be able to form hydrogen bonding with several types of polymers
containing a hydrogen acceptor group while felodipine itself functions as a donor (Marsac et al.
2010; Karavas et al. 2006; Konno and Taylor 2006; Teberekidis and Sigalas 2007). FT-IR
spectra illustrated the characteristic peaks for felodipine (Fig. 4-14). (N-H) Stretching band at
3366 cm-1 had disappeared from the extrudate and was clearly seen at the physical mixture. This
indicates that a stronger hydrogen bond has occurred between the (–NH) of felodipine and the
(C=O) of the pyrrolidone group in Kollidon® VA 64.
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Fig. 4-14: FTIR analysis of pure Lutrol® F 68, pure Kollidon® VA 64, Pure Felodipine, the
physical mixture of 30% Felodipine and the milled extrudate containing 30% Felodipine

GSF has two characteristic peaks at 1,704 cm and 1,655 cm (Fig. 4-15). The first peak is
corresponding to stretching of the carbonyl group of the benzofuran and the second by stretching
of the carbonyl group of cyclohexene. This was in agreement with work of Nair et al (Nair et al.
2001). The carbonyl peak at 1,704 cm−1 is a clearly seen and the carbonyl peak at 1,658 cm−1 is
overlapped by strong vibration of (-COO) at 1666 cm-1 which belongs to the vinyl pyrrolidone
monomer of the polymer. Griseofulvin did not appear to interact with the polymer matrices.
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Fig. 4-15: FTIR analysis of pure Lutrol® F 68, pure Kollidon® VA 64, Pure Griseofulvin,
the physical mixture of 30% Griseofulvin and the milled extrudate containing 30%
Griseofulvin
4.4 Conclusion
DSC & PXRD data verified the formation of amorphous solid dispersions of different drugs with
varied melting point which were extruded at the same extrusion conditions. Dissolution studies
revealed that the extrudates with Lutrol® F grades exhibited faster and higher releases than without
Lutrol® F grades. Polymer melt extrudates of Kollidon®VA64 incorporated with Lutrol® F grades
demonstrated a promising role in enhancing the release of poorly water-soluble drugs with varied
melting points.
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CHAPTER 5
SUMMARY AND CONCLUSIONS

2- Preparation and Evaluation of Hot-Melt Extruded Patient-Centric Ketoprofen Minitablets
HME was demonstrated as a viable technique with a potential to develop novel Mini-tablets
containing various amounts of KPR with the taste-masking polymer Eudragit® E PO.
Eudragit® E PO containing ketoprofen at various percentages were successfully
formulated, melt extruded and cut into mini-tablets via a continuous process of pelletization
with an adapted pelletizer directly connected to a hot-melt extruder.
The reduced drug release at salivary pH correlated well with Astree e-Tongue studies for
taste masking efficiency.
Intermolecular interactions between oppositely charged compounds may have reduced the
bitter taste of the drug and increased the stability of the formulation.
The melt-extruded mini-tablets containing up to 40% drug load were found to be physically
and chemically stable for a period of 3 months.
These results confirm the promising role of Eudragit® EPO to produce novel pediatric and
geriatric dosage forms for taste masking applications.
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3. Optimization of Hot Melt Extrusion Parameters for Sphericity and Hardness on Polymeric
Face-Cut Pellets
HME was demonstrated as a viable technique with a potential to develop novel face-cut
pellets containing carbamazepine with Soluplus® as a polymeric carrier.
The Box-Behnken experimental design was successfully utilized for the optimization of
HME connected to a face-cut pelletizer, required only 17 experiments.
Pellets with satisfactory physico-mechanical characteristics were successfully prepared by
Melt Extrusion/ Face-cut Pelletization using the optimized conditions.
The present study discusses the development of novel, “ready to fill” face-cut pellets as
final/finished drug products using hot melt extrusion techniques
These studies may be beneficial for optimizing the manufacture of other types of dosage
forms.
Changing face cutter speed is a point of interest for future work

4. Influence of Lutrol® F Grades (Poloxamer) on Solubility of Hot Melt Extruded Kollidon®
VA64 Drug-incorporated Matrices
Three poorly soluble drugs are used and solid dispersion systems were produced with
Kollidon® VA 64 and Lutrol® F grads using Hot Melt Extrusion.
DSC & PXRD data verified the formation of amorphous solid dispersions of different drugs
with varied melting point which were extruded at the same extrusion conditions.
Extrusion temperature were found to have a significant effect on the specific surface area
of fenofibrate formulations.
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Dissolution studies revealed that the extrudates with Lutrol® F grades exhibited faster and
higher releases than without Lutrol® F grades
FT-IR studies showed a stronger hydrogen bond has occurred between felodipine and
Kollidon® VA 64. In contrast, Fenofibrate and Griseofulvin did not appear to interact with
the polymer matrices.
Polymer melt extrudates of Kollidon®VA64 incorporated with Lutrol® F grades
demonstrated a promising role in enhancing the release of poorly water-soluble drugs with
varied melting points.
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